CN115135199A - 多层化妆垫的方法和系统及其用途 - Google Patents
多层化妆垫的方法和系统及其用途 Download PDFInfo
- Publication number
- CN115135199A CN115135199A CN202180008337.5A CN202180008337A CN115135199A CN 115135199 A CN115135199 A CN 115135199A CN 202180008337 A CN202180008337 A CN 202180008337A CN 115135199 A CN115135199 A CN 115135199A
- Authority
- CN
- China
- Prior art keywords
- cosmetic
- pad
- layer
- cosmetic pad
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 325
- 238000000034 method Methods 0.000 title claims abstract description 23
- 238000010438 heat treatment Methods 0.000 claims abstract description 118
- 239000000463 material Substances 0.000 claims abstract description 65
- 238000009423 ventilation Methods 0.000 claims abstract description 31
- 210000004209 hair Anatomy 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims description 127
- 238000009472 formulation Methods 0.000 claims description 98
- -1 serum Substances 0.000 claims description 69
- 238000009792 diffusion process Methods 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 229940000033 dermatological agent Drugs 0.000 claims description 16
- 239000003241 dermatological agent Substances 0.000 claims description 16
- 239000006210 lotion Substances 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 10
- 229940088594 vitamin Drugs 0.000 claims description 10
- 229930003231 vitamin Natural products 0.000 claims description 10
- 235000013343 vitamin Nutrition 0.000 claims description 10
- 239000011782 vitamin Substances 0.000 claims description 10
- 239000000499 gel Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 230000009977 dual effect Effects 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 108010064851 Plant Proteins Proteins 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 108010002537 Fruit Proteins Proteins 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 82
- 210000003811 finger Anatomy 0.000 description 40
- 239000000516 sunscreening agent Substances 0.000 description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
- 239000004698 Polyethylene Substances 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 17
- 229920000573 polyethylene Polymers 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 230000000475 sunscreen effect Effects 0.000 description 17
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 16
- 239000004743 Polypropylene Substances 0.000 description 15
- 230000007246 mechanism Effects 0.000 description 15
- 229920001155 polypropylene Polymers 0.000 description 15
- 229920000139 polyethylene terephthalate Polymers 0.000 description 14
- 239000005020 polyethylene terephthalate Substances 0.000 description 14
- 239000003921 oil Substances 0.000 description 13
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 12
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 12
- 230000004888 barrier function Effects 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- CRDAMVZIKSXKFV-YFVJMOTDSA-N (2-trans,6-trans)-farnesol Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO CRDAMVZIKSXKFV-YFVJMOTDSA-N 0.000 description 10
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 10
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 9
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 9
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 9
- 206010040844 Skin exfoliation Diseases 0.000 description 9
- 229940036350 bisabolol Drugs 0.000 description 9
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 9
- 229960003722 doxycycline Drugs 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 229940043259 farnesol Drugs 0.000 description 9
- 229930002886 farnesol Natural products 0.000 description 9
- 239000010408 film Substances 0.000 description 9
- 229930003935 flavonoid Natural products 0.000 description 9
- 235000017173 flavonoids Nutrition 0.000 description 9
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 150000004492 retinoid derivatives Chemical class 0.000 description 9
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 9
- 229930003537 Vitamin B3 Natural products 0.000 description 8
- 239000002260 anti-inflammatory agent Substances 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 239000002738 chelating agent Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 8
- 229960003512 nicotinic acid Drugs 0.000 description 8
- 229960004889 salicylic acid Drugs 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 229930003799 tocopherol Natural products 0.000 description 8
- 235000010384 tocopherol Nutrition 0.000 description 8
- 229960001295 tocopherol Drugs 0.000 description 8
- 239000011732 tocopherol Substances 0.000 description 8
- 235000019160 vitamin B3 Nutrition 0.000 description 8
- 239000011708 vitamin B3 Substances 0.000 description 8
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 7
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 7
- 229940121363 anti-inflammatory agent Drugs 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- CGIHFIDULQUVJG-UHFFFAOYSA-N phytantriol Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)(O)C(O)CO CGIHFIDULQUVJG-UHFFFAOYSA-N 0.000 description 7
- CGIHFIDULQUVJG-VNTMZGSJSA-N phytantriol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(O)[C@H](O)CO CGIHFIDULQUVJG-VNTMZGSJSA-N 0.000 description 7
- 229920000728 polyester Polymers 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 6
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 6
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 6
- 150000001789 chalcones Chemical class 0.000 description 6
- 235000005513 chalcones Nutrition 0.000 description 6
- 238000004140 cleaning Methods 0.000 description 6
- 238000004299 exfoliation Methods 0.000 description 6
- 150000002215 flavonoids Chemical class 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 6
- 229930002330 retinoic acid Natural products 0.000 description 6
- 229960003471 retinol Drugs 0.000 description 6
- 235000020944 retinol Nutrition 0.000 description 6
- 239000011607 retinol Substances 0.000 description 6
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 229960000458 allantoin Drugs 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 239000007854 depigmenting agent Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 5
- 229940101267 panthenol Drugs 0.000 description 5
- 235000020957 pantothenol Nutrition 0.000 description 5
- 239000011619 pantothenol Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000002516 radical scavenger Substances 0.000 description 5
- 229960001727 tretinoin Drugs 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- 235000002961 Aloe barbadensis Nutrition 0.000 description 4
- 244000144927 Aloe barbadensis Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000001994 activation Methods 0.000 description 4
- 235000011399 aloe vera Nutrition 0.000 description 4
- 230000003255 anti-acne Effects 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000003212 astringent agent Substances 0.000 description 4
- 229960005193 avobenzone Drugs 0.000 description 4
- 230000003750 conditioning effect Effects 0.000 description 4
- 239000008406 cosmetic ingredient Substances 0.000 description 4
- 229940120503 dihydroxyacetone Drugs 0.000 description 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 4
- 229930003949 flavanone Natural products 0.000 description 4
- 150000002208 flavanones Chemical class 0.000 description 4
- 235000011981 flavanones Nutrition 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 235000019136 lipoic acid Nutrition 0.000 description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 4
- 229960000601 octocrylene Drugs 0.000 description 4
- 239000011164 primary particle Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 4
- 229940075554 sorbate Drugs 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 229960002663 thioctic acid Drugs 0.000 description 4
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 3
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 3
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 3
- 239000004342 Benzoyl peroxide Substances 0.000 description 3
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 3
- 239000001263 FEMA 3042 Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 3
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 3
- 235000004347 Perilla Nutrition 0.000 description 3
- 244000124853 Perilla frutescens Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 3
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 235000019400 benzoyl peroxide Nutrition 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 150000004777 chromones Chemical class 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 229940068517 fruit extracts Drugs 0.000 description 3
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 3
- 238000009499 grossing Methods 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000013003 healing agent Substances 0.000 description 3
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 3
- 150000001261 hydroxy acids Chemical class 0.000 description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 3
- 150000002515 isoflavone derivatives Chemical class 0.000 description 3
- 235000008696 isoflavones Nutrition 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 3
- CBKLICUQYUTWQL-XWGBWKJCSA-N methyl (3s,4r)-3-methyl-1-(2-phenylethyl)-4-(n-propanoylanilino)piperidine-4-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.CCC(=O)N([C@]1([C@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 CBKLICUQYUTWQL-XWGBWKJCSA-N 0.000 description 3
- 229960002509 miconazole Drugs 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229940108325 retinyl palmitate Drugs 0.000 description 3
- 235000019172 retinyl palmitate Nutrition 0.000 description 3
- 239000011769 retinyl palmitate Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000003352 sequestering agent Substances 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229940033123 tannic acid Drugs 0.000 description 3
- 235000015523 tannic acid Nutrition 0.000 description 3
- 229920002258 tannic acid Polymers 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 3
- 238000013022 venting Methods 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- 239000002888 zwitterionic surfactant Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- RBOZTFPIXJBLPK-HWAYABPNSA-N (NE)-N-[(2E)-1,2-bis(furan-2-yl)-2-hydroxyiminoethylidene]hydroxylamine Chemical compound O\N=C(/C(=N\O)/C1=CC=CO1)\C1=CC=CO1 RBOZTFPIXJBLPK-HWAYABPNSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- OAAZUWWNSYWWHG-UHFFFAOYSA-N 1-phenoxypropan-1-ol Chemical compound CCC(O)OC1=CC=CC=C1 OAAZUWWNSYWWHG-UHFFFAOYSA-N 0.000 description 2
- IBLKWZIFZMJLFL-UHFFFAOYSA-N 1-phenoxypropan-2-ol Chemical compound CC(O)COC1=CC=CC=C1 IBLKWZIFZMJLFL-UHFFFAOYSA-N 0.000 description 2
- LALVCWMSKLEQMK-UHFFFAOYSA-N 1-phenyl-3-(4-propan-2-ylphenyl)propane-1,3-dione Chemical compound C1=CC(C(C)C)=CC=C1C(=O)CC(=O)C1=CC=CC=C1 LALVCWMSKLEQMK-UHFFFAOYSA-N 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- JTXMVXSTHSMVQF-UHFFFAOYSA-N 2-acetyloxyethyl acetate Chemical compound CC(=O)OCCOC(C)=O JTXMVXSTHSMVQF-UHFFFAOYSA-N 0.000 description 2
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 2
- ABFVFIZSXKRBRL-UHFFFAOYSA-N 2-hydroxy-2-phenyl-3h-chromen-4-one Chemical class C1C(=O)C2=CC=CC=C2OC1(O)C1=CC=CC=C1 ABFVFIZSXKRBRL-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- FSEXLNMNADBYJU-UHFFFAOYSA-N 2-phenylquinoline Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=N1 FSEXLNMNADBYJU-UHFFFAOYSA-N 0.000 description 2
- SEBPXHSZHLFWRL-UHFFFAOYSA-N 3,4-dihydro-2,2,5,7,8-pentamethyl-2h-1-benzopyran-6-ol Chemical compound O1C(C)(C)CCC2=C1C(C)=C(C)C(O)=C2C SEBPXHSZHLFWRL-UHFFFAOYSA-N 0.000 description 2
- IJFXRHURBJZNAO-UHFFFAOYSA-N 3-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC(O)=C1 IJFXRHURBJZNAO-UHFFFAOYSA-N 0.000 description 2
- YDIYEOMDOWUDTJ-UHFFFAOYSA-N 4-(dimethylamino)benzoic acid Chemical compound CN(C)C1=CC=C(C(O)=O)C=C1 YDIYEOMDOWUDTJ-UHFFFAOYSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-M 4-aminobenzoate Chemical compound NC1=CC=C(C([O-])=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-M 0.000 description 2
- VXIXUWQIVKSKSA-UHFFFAOYSA-N 4-hydroxycoumarin Chemical compound C1=CC=CC2=C1OC(=O)C=C2O VXIXUWQIVKSKSA-UHFFFAOYSA-N 0.000 description 2
- ATEFPOUAMCWAQS-UHFFFAOYSA-N 7,8-dihydroxycoumarin Chemical compound C1=CC(=O)OC2=C(O)C(O)=CC=C21 ATEFPOUAMCWAQS-UHFFFAOYSA-N 0.000 description 2
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- FSNVAJOPUDVQAR-AVGNSLFASA-N Arg-Lys-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FSNVAJOPUDVQAR-AVGNSLFASA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 2
- 108010065839 Capreomycin Proteins 0.000 description 2
- 108010087806 Carnosine Proteins 0.000 description 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 235000004866 D-panthenol Nutrition 0.000 description 2
- 239000011703 D-panthenol Substances 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 239000005770 Eugenol Substances 0.000 description 2
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 150000000996 L-ascorbic acids Chemical class 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- SCMSRHIBVBIECI-UHFFFAOYSA-N [2-hydroxy-4-(2-hydroxyethoxy)phenyl]-phenylmethanone Chemical compound OC1=CC(OCCO)=CC=C1C(=O)C1=CC=CC=C1 SCMSRHIBVBIECI-UHFFFAOYSA-N 0.000 description 2
- 239000003082 abrasive agent Substances 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 229960002916 adapalene Drugs 0.000 description 2
- 125000005210 alkyl ammonium group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 2
- 229940064734 aminobenzoate Drugs 0.000 description 2
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 235000020221 chamomile extract Nutrition 0.000 description 2
- 229940119217 chamomile extract Drugs 0.000 description 2
- 235000019480 chamomile oil Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 239000010634 clove oil Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- YBGKGTOOPNQOKH-UHFFFAOYSA-N daphnetin Natural products OC1=CC=CC2=C1OC(=O)C=C2O YBGKGTOOPNQOKH-UHFFFAOYSA-N 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 229960003949 dexpanthenol Drugs 0.000 description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 239000010642 eucalyptus oil Substances 0.000 description 2
- 229940044949 eucalyptus oil Drugs 0.000 description 2
- 229960002217 eugenol Drugs 0.000 description 2
- 238000003804 extraction from natural source Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 2
- 229960002011 fludrocortisone Drugs 0.000 description 2
- 229960001347 fluocinolone acetonide Drugs 0.000 description 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 2
- 229960000785 fluocinonide Drugs 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 239000000118 hair dye Substances 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- VAMFXQBUQXONLZ-UHFFFAOYSA-N icos-1-ene Chemical compound CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- 229960003151 mercaptamine Drugs 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229940053050 neomycin sulfate Drugs 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- YAGMLECKUBJRNO-UHFFFAOYSA-N octyl 4-(dimethylamino)benzoate Chemical compound CCCCCCCCOC(=O)C1=CC=C(N(C)C)C=C1 YAGMLECKUBJRNO-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 2
- 229960004448 pentamidine Drugs 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229940106026 phenoxyisopropanol Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
- 229940068041 phytic acid Drugs 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 239000000467 phytic acid Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229950001046 piroctone Drugs 0.000 description 2
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920005903 polyol mixture Polymers 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 229960000342 retinol acetate Drugs 0.000 description 2
- 235000019173 retinyl acetate Nutrition 0.000 description 2
- 239000011770 retinyl acetate Substances 0.000 description 2
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 2
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 2
- 239000011833 salt mixture Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 229960004245 silymarin Drugs 0.000 description 2
- 235000017700 silymarin Nutrition 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 230000037075 skin appearance Effects 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 2
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 229960000565 tazarotene Drugs 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical class C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 2
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- DEQUKPCANKRTPZ-UHFFFAOYSA-N (2,3-dihydroxyphenyl)-phenylmethanone Chemical class OC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1O DEQUKPCANKRTPZ-UHFFFAOYSA-N 0.000 description 1
- HQEPZWYPQQKFLU-UHFFFAOYSA-N (2,6-dihydroxyphenyl)-phenylmethanone Chemical class OC1=CC=CC(O)=C1C(=O)C1=CC=CC=C1 HQEPZWYPQQKFLU-UHFFFAOYSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- HQHAQXRBWDECIC-FVPAAFGUSA-N (2e)-5,5-dihydroxy-2-[(z)-3-hydroxy-3-phenylprop-2-enylidene]cyclohex-3-en-1-one Chemical compound C=1C=CC=CC=1C(/O)=C/C=C1\C=CC(O)(O)CC1=O HQHAQXRBWDECIC-FVPAAFGUSA-N 0.000 description 1
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- PDHSAQOQVUXZGQ-JKSUJKDBSA-N (2r,3s)-2-(3,4-dihydroxyphenyl)-3-methoxy-3,4-dihydro-2h-chromene-5,7-diol Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2OC)=CC=C(O)C(O)=C1 PDHSAQOQVUXZGQ-JKSUJKDBSA-N 0.000 description 1
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical group CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 1
- ZEUUPKVZFKBXPW-TWDWGCDDSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N ZEUUPKVZFKBXPW-TWDWGCDDSA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- VXPSARQTYDZXAO-CCHMMTNSSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O VXPSARQTYDZXAO-CCHMMTNSSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 description 1
- VFOKYTYWXOYPOX-PTNGSMBKSA-N (e)-2,3-diphenylprop-2-enenitrile Chemical compound C=1C=CC=CC=1C(/C#N)=C\C1=CC=CC=C1 VFOKYTYWXOYPOX-PTNGSMBKSA-N 0.000 description 1
- UDOOPSJCRMKSGL-ZHACJKMWSA-N (e)-3-(2-hydroxyphenyl)-1-phenylprop-2-en-1-one Chemical compound OC1=CC=CC=C1\C=C\C(=O)C1=CC=CC=C1 UDOOPSJCRMKSGL-ZHACJKMWSA-N 0.000 description 1
- MSDGTBGJKOTHCN-SOFGYWHQSA-N (e)-3-phenyl-1-(2,3,4-trihydroxyphenyl)prop-2-en-1-one Chemical compound OC1=C(O)C(O)=CC=C1C(=O)\C=C\C1=CC=CC=C1 MSDGTBGJKOTHCN-SOFGYWHQSA-N 0.000 description 1
- MMEXPSCGRYPZKY-UHFFFAOYSA-N 1-(3-bromoindazol-2-yl)ethanone Chemical compound C1=CC=CC2=C(Br)N(C(=O)C)N=C21 MMEXPSCGRYPZKY-UHFFFAOYSA-N 0.000 description 1
- HZSOUUXSRHAEDG-UHFFFAOYSA-N 1-amino-2,4-dihydroxypentan-3-one Chemical compound CC(O)C(=O)C(O)CN HZSOUUXSRHAEDG-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- SERQFHAVLYPAHE-UHFFFAOYSA-N 1-phenyl-3-(2,3,4-trihydroxyphenyl)prop-2-en-1-one Chemical class OC1=C(O)C(O)=CC=C1C=CC(=O)C1=CC=CC=C1 SERQFHAVLYPAHE-UHFFFAOYSA-N 0.000 description 1
- GUPMCMZMDAGSPF-UHFFFAOYSA-N 1-phenylbuta-1,3-dienylbenzene Chemical compound C=1C=CC=CC=1[C](C=C[CH2])C1=CC=CC=C1 GUPMCMZMDAGSPF-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- UGAGPNKCDRTDHP-UHFFFAOYSA-N 16-hydroxyhexadecanoic acid Chemical compound OCCCCCCCCCCCCCCCC(O)=O UGAGPNKCDRTDHP-UHFFFAOYSA-N 0.000 description 1
- VFGLRVWAOAFUGZ-UHFFFAOYSA-N 2,3-dihydroxy-1,3-diphenylprop-2-en-1-one Chemical class C=1C=CC=CC=1C(=O)C(O)=C(O)C1=CC=CC=C1 VFGLRVWAOAFUGZ-UHFFFAOYSA-N 0.000 description 1
- XPKVYKWWLONHDF-UHFFFAOYSA-N 2,3-dihydroxy-3-(2-hydroxyphenyl)prop-2-enoic acid Chemical class OC(=O)C(O)=C(O)C1=CC=CC=C1O XPKVYKWWLONHDF-UHFFFAOYSA-N 0.000 description 1
- DRBARRGCABOUIE-UHFFFAOYSA-N 2,3-dihydroxy-3-phenylprop-2-enoic acid Chemical class OC(=O)C(O)=C(O)C1=CC=CC=C1 DRBARRGCABOUIE-UHFFFAOYSA-N 0.000 description 1
- WZPLEIAOQJXZJX-UHFFFAOYSA-N 2,3-dihydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C(O)=CC2=C1 WZPLEIAOQJXZJX-UHFFFAOYSA-N 0.000 description 1
- ZXDDPOHVAMWLBH-UHFFFAOYSA-N 2,4-Dihydroxybenzophenone Chemical compound OC1=CC(O)=CC=C1C(=O)C1=CC=CC=C1 ZXDDPOHVAMWLBH-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- GTKJMOBSGIXALB-UHFFFAOYSA-N 2,7-dihydroxy-2-phenyl-3H-chromen-4-one Chemical compound OC1=CC=C2C(CC(OC2=C1)(C1=CC=CC=C1)O)=O GTKJMOBSGIXALB-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- QHDDZRCEINZAMT-UHFFFAOYSA-N 2-[4-(dimethylamino)phenyl]-1,3-benzoxazole-5-sulfonic acid Chemical compound C1=CC(N(C)C)=CC=C1C1=NC2=CC(S(O)(=O)=O)=CC=C2O1 QHDDZRCEINZAMT-UHFFFAOYSA-N 0.000 description 1
- TYIOVYZMKITKRO-UHFFFAOYSA-N 2-[hexadecyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O TYIOVYZMKITKRO-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- OGQYJDHTHFAPRN-UHFFFAOYSA-N 2-fluoro-6-(trifluoromethyl)benzonitrile Chemical compound FC1=CC=CC(C(F)(F)F)=C1C#N OGQYJDHTHFAPRN-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 1
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 1
- JCTNVNANPZAULC-UHFFFAOYSA-N 2-methylbenzo[e][1,3]benzoxazole Chemical compound C1=CC=C2C(N=C(O3)C)=C3C=CC2=C1 JCTNVNANPZAULC-UHFFFAOYSA-N 0.000 description 1
- FIISKTXZUZBTRC-UHFFFAOYSA-N 2-phenyl-1,3-benzoxazole Chemical compound C1=CC=CC=C1C1=NC2=CC=CC=C2O1 FIISKTXZUZBTRC-UHFFFAOYSA-N 0.000 description 1
- DIIDIHMSJICLIZ-UHFFFAOYSA-N 2-sulfanylethylcarbamic acid Chemical compound OC(=O)NCCS DIIDIHMSJICLIZ-UHFFFAOYSA-N 0.000 description 1
- ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 1
- TUATYNXRYJTQTQ-BVRBKCERSA-N 3,6-diamino-n-[[(2s,5s,8z,11s,15s)-15-amino-11-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;3,6-diamino-n-[[(2s,5s,8z,11s,15s)-15-a Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1C1NC(=N)NCC1.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1C1NC(=N)NCC1 TUATYNXRYJTQTQ-BVRBKCERSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical class C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- FCBJFMXAMYKDOA-UHFFFAOYSA-N 3-(2,3-dihydroxyphenyl)-1-phenylprop-2-en-1-one Chemical class OC1=CC=CC(C=CC(=O)C=2C=CC=CC=2)=C1O FCBJFMXAMYKDOA-UHFFFAOYSA-N 0.000 description 1
- LKNPFZQVNZFLIC-UHFFFAOYSA-N 3-(2,4-dihydroxyphenyl)-1-phenylprop-2-en-1-one Chemical class OC1=CC(O)=CC=C1C=CC(=O)C1=CC=CC=C1 LKNPFZQVNZFLIC-UHFFFAOYSA-N 0.000 description 1
- APPPFSLINJPIJH-UHFFFAOYSA-N 3-(2,5-dihydroxyphenyl)-1-phenylprop-2-en-1-one Chemical class OC1=CC=C(O)C(C=CC(=O)C=2C=CC=CC=2)=C1 APPPFSLINJPIJH-UHFFFAOYSA-N 0.000 description 1
- UDOOPSJCRMKSGL-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-1-phenylprop-2-en-1-one Chemical class OC1=CC=CC=C1C=CC(=O)C1=CC=CC=C1 UDOOPSJCRMKSGL-UHFFFAOYSA-N 0.000 description 1
- USWINTIHFQKJTR-UHFFFAOYSA-N 3-hydroxynaphthalene-2,7-disulfonic acid Chemical class C1=C(S(O)(=O)=O)C=C2C=C(S(O)(=O)=O)C(O)=CC2=C1 USWINTIHFQKJTR-UHFFFAOYSA-N 0.000 description 1
- NJLKZOZYTRRDBO-UHFFFAOYSA-N 3-iodopropyl n-butylcarbamate Chemical compound CCCCNC(=O)OCCCI NJLKZOZYTRRDBO-UHFFFAOYSA-N 0.000 description 1
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical class OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 1
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 description 1
- MSTDXOZUKAQDRL-UHFFFAOYSA-N 4-Chromanone Chemical class C1=CC=C2C(=O)CCOC2=C1 MSTDXOZUKAQDRL-UHFFFAOYSA-N 0.000 description 1
- HRCTWBSVGHLFKF-UHFFFAOYSA-N 4-[bis(2-ethylhexyl)amino]benzoic acid Chemical compound CCCCC(CC)CN(CC(CC)CCCC)C1=CC=C(C(O)=O)C=C1 HRCTWBSVGHLFKF-UHFFFAOYSA-N 0.000 description 1
- KWCHGHCWERZDGX-UHFFFAOYSA-N 4-amino-3-hydroxybutan-2-one Chemical compound CC(=O)C(O)CN KWCHGHCWERZDGX-UHFFFAOYSA-N 0.000 description 1
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 1
- OBNZPZAOTISUNM-UHFFFAOYSA-N 4-chloro-1,6-dimethylcyclohexa-2,4-dien-1-ol Chemical compound ClC1=CC(C(C=C1)(C)O)C OBNZPZAOTISUNM-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- PWWCDTYUYPOAIU-DHZHZOJOSA-N 4-hydroxychalcone Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=CC=C1 PWWCDTYUYPOAIU-DHZHZOJOSA-N 0.000 description 1
- OGPXFMUUEMXTAR-UHFFFAOYSA-N 4-methoxy-2-phenyl-4h-chromen-3-one Chemical class O1C2=CC=CC=C2C(OC)C(=O)C1C1=CC=CC=C1 OGPXFMUUEMXTAR-UHFFFAOYSA-N 0.000 description 1
- FRRYMYQANNFABF-UHFFFAOYSA-N 4-oxo-6-propan-2-ylchromene-3-carbaldehyde Chemical compound O1C=C(C=O)C(=O)C2=CC(C(C)C)=CC=C21 FRRYMYQANNFABF-UHFFFAOYSA-N 0.000 description 1
- FSMYWBQIMDSGQP-UHFFFAOYSA-N 4-oxochromene-3-carbaldehyde Chemical compound C1=CC=C2C(=O)C(C=O)=COC2=C1 FSMYWBQIMDSGQP-UHFFFAOYSA-N 0.000 description 1
- IVESJZYRXSGNKY-UHFFFAOYSA-N 5-(trimethoxymethyl)bicyclo[2.2.1]hept-2-ene Chemical compound C1C2C(C(OC)(OC)OC)CC1C=C2 IVESJZYRXSGNKY-UHFFFAOYSA-N 0.000 description 1
- YLLFUILNISGLHO-UHFFFAOYSA-N 5-methoxy-2-phenyl-2,3-dihydrochromen-4-one Chemical class C1C(=O)C=2C(OC)=CC=CC=2OC1C1=CC=CC=C1 YLLFUILNISGLHO-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- KVOJTUXGYQVLAJ-UHFFFAOYSA-N 6,7-dihydroxy-4-methylcoumarin Chemical compound C1=C(O)C(O)=CC2=C1OC(=O)C=C2C KVOJTUXGYQVLAJ-UHFFFAOYSA-N 0.000 description 1
- IRUHWRSITUYICV-UHFFFAOYSA-N 6-hydroxy-4-methylchromen-2-one Chemical compound C1=CC(O)=CC2=C1OC(=O)C=C2C IRUHWRSITUYICV-UHFFFAOYSA-N 0.000 description 1
- HRRVLSKRYVIEPR-UHFFFAOYSA-N 6-hydroxy-5-nitroso-1H-pyrimidine-2,4-dione Chemical compound OC1=NC(O)=C(N=O)C(O)=N1 HRRVLSKRYVIEPR-UHFFFAOYSA-N 0.000 description 1
- XYHWPQUEOOBIOW-UHFFFAOYSA-N 6-hydroxyflavanone Chemical class C1C(=O)C2=CC(O)=CC=C2OC1C1=CC=CC=C1 XYHWPQUEOOBIOW-UHFFFAOYSA-N 0.000 description 1
- YURQMHCZHLMHIB-UHFFFAOYSA-N 6-methoxy-2-phenyl-2,3-dihydrochromen-4-one Chemical class C1C(=O)C2=CC(OC)=CC=C2OC1C1=CC=CC=C1 YURQMHCZHLMHIB-UHFFFAOYSA-N 0.000 description 1
- VFMMPHCGEFXGIP-UHFFFAOYSA-N 7,8-Benzoflavone Chemical compound O1C2=C3C=CC=CC3=CC=C2C(=O)C=C1C1=CC=CC=C1 VFMMPHCGEFXGIP-UHFFFAOYSA-N 0.000 description 1
- SWAJPHCXKPCPQZ-UHFFFAOYSA-N 7-hydroxyflavanone Chemical class O1C2=CC(O)=CC=C2C(=O)CC1C1=CC=CC=C1 SWAJPHCXKPCPQZ-UHFFFAOYSA-N 0.000 description 1
- DOBIZWYVJFIYOV-UHFFFAOYSA-N 7-hydroxynaphthalene-1,3-disulfonic acid Chemical class C1=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=CC(O)=CC=C21 DOBIZWYVJFIYOV-UHFFFAOYSA-N 0.000 description 1
- VYESEQLQFXUROZ-UHFFFAOYSA-N 7-methoxy-2-phenyl-2,3-dihydrochromen-4-one Chemical class O1C2=CC(OC)=CC=C2C(=O)CC1C1=CC=CC=C1 VYESEQLQFXUROZ-UHFFFAOYSA-N 0.000 description 1
- PCFGFYKGPMQDBX-FEKONODYSA-N 78355-50-7 Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 PCFGFYKGPMQDBX-FEKONODYSA-N 0.000 description 1
- 150000004325 8-hydroxyquinolines Chemical class 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 description 1
- 240000005343 Azadirachta indica Species 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- UONRGKALIXPQDW-UHFFFAOYSA-N C1=CC(N(C)CC(CC)CCCC)=CC=C1C(=O)OCCOC1=CC=C(C(=O)CC(=O)C=2C=CC=CC=2)C=C1 Chemical compound C1=CC(N(C)CC(CC)CCCC)=CC=C1C(=O)OCCOC1=CC=C(C(=O)CC(=O)C=2C=CC=CC=2)C=C1 UONRGKALIXPQDW-UHFFFAOYSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- JXCOSKURGJMQSG-AZQJGLEESA-N Cortolone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)[C@@H](O)CO)[C@@H]4[C@@H]3CC[C@@H]21 JXCOSKURGJMQSG-AZQJGLEESA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- VPGRYOFKCNULNK-ACXQXYJUSA-N Deoxycorticosterone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)COC(=O)C)[C@@]1(C)CC2 VPGRYOFKCNULNK-ACXQXYJUSA-N 0.000 description 1
- 229920001174 Diethylhydroxylamine Polymers 0.000 description 1
- HHJIUUAMYGBVSD-YTFFSALGSA-N Diflucortolone valerate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)CCCC)[C@@]2(C)C[C@@H]1O HHJIUUAMYGBVSD-YTFFSALGSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 235000003935 Hippophae Nutrition 0.000 description 1
- 241000229143 Hippophae Species 0.000 description 1
- FDQYIRHBVVUTJF-ZETCQYMHSA-N His-Gly-Gly Chemical compound [O-]C(=O)CNC(=O)CNC(=O)[C@@H]([NH3+])CC1=CN=CN1 FDQYIRHBVVUTJF-ZETCQYMHSA-N 0.000 description 1
- DLVOSEUFIRPIRM-KAQKJVHQSA-N Hydrocortisone cypionate Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(CCC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCC1CCCC1 DLVOSEUFIRPIRM-KAQKJVHQSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 241001100935 Ilex purpurea Species 0.000 description 1
- 235000003366 Ilex purpurea Nutrition 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- 241000830535 Ligustrum lucidum Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 235000013500 Melia azadirachta Nutrition 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000008898 Morinda citrifolia Nutrition 0.000 description 1
- 244000131360 Morinda citrifolia Species 0.000 description 1
- 235000011347 Moringa oleifera Nutrition 0.000 description 1
- 244000179886 Moringa oleifera Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- USSFUVKEHXDAPM-UHFFFAOYSA-N Nicotinamide N-oxide Chemical compound NC(=O)C1=CC=C[N+]([O-])=C1 USSFUVKEHXDAPM-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 229930182473 O-glycoside Chemical group 0.000 description 1
- 150000008444 O-glycosides Chemical group 0.000 description 1
- VQNVKIIBXVSJAP-UHFFFAOYSA-N OC=1CC(C2=CC=CC=C2C=1O)=O Chemical compound OC=1CC(C2=CC=CC=C2C=1O)=O VQNVKIIBXVSJAP-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical class C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 235000005247 Rumex japonicus Nutrition 0.000 description 1
- 244000189123 Rumex japonicus Species 0.000 description 1
- 235000002953 Saxifraga stolonifera Nutrition 0.000 description 1
- 244000288377 Saxifraga stolonifera Species 0.000 description 1
- 241000304432 Sedum sarmentosum Species 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000006694 Stellaria media Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 208000031439 Striae Distensae Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- GTTSNKDQDACYLV-UHFFFAOYSA-N Trihydroxybutane Chemical compound CCCC(O)(O)O GTTSNKDQDACYLV-UHFFFAOYSA-N 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 230000037338 UVA radiation Effects 0.000 description 1
- 244000003892 Vaccinium erythrocarpum Species 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 1
- XDLGATIAMPGERU-UHFFFAOYSA-N [2-[[4-[[7,7-dimethyl-3-oxo-4-(sulfomethyl)-2-bicyclo[2.2.1]heptanyl]methyl]phenyl]methyl]-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound CC1(C)C2CCC1(CS(O)(=O)=O)C(=O)C2CC(C=C1)=CC=C1CC1C(=O)C2(CS(O)(=O)=O)CCC1C2(C)C XDLGATIAMPGERU-UHFFFAOYSA-N 0.000 description 1
- NBVZMBLJRHUOJR-UHFFFAOYSA-N [amino-[4-[6-[4-[amino(azaniumylidene)methyl]phenoxy]hexoxy]phenyl]methylidene]azanium;2-hydroxyethanesulfonate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 NBVZMBLJRHUOJR-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 description 1
- GUAFOGOEJLSQBT-UHFFFAOYSA-N aesculetin dimethyl ether Natural products C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000014104 aloe vera supplement Nutrition 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 1
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 1
- 229960001280 amantadine hydrochloride Drugs 0.000 description 1
- 229960002805 amantadine sulfate Drugs 0.000 description 1
- MYWTWSQFJLXGGQ-UHFFFAOYSA-N amantadine sulfate Chemical compound OS(O)(=O)=O.C1C(C2)CC3CC2CC1(N)C3.C1C(C2)CC3CC2CC1(N)C3 MYWTWSQFJLXGGQ-UHFFFAOYSA-N 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960001656 amikacin sulfate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 229940067599 ascorbyl glucoside Drugs 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 150000001996 bisabolol derivatives Chemical class 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009529 body temperature measurement Methods 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- HEIBHROOHCJHCD-MDZDMXLPSA-N butyl (e)-2,4-dioxo-6-phenylhex-5-enoate Chemical compound CCCCOC(=O)C(=O)CC(=O)\C=C\C1=CC=CC=C1 HEIBHROOHCJHCD-MDZDMXLPSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 229960002968 capreomycin sulfate Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960003185 chlortetracycline hydrochloride Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960001200 clindamycin hydrochloride Drugs 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- FZCHYNWYXKICIO-FZNHGJLXSA-N cortisol 17-valerate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O FZCHYNWYXKICIO-FZNHGJLXSA-N 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 239000013527 degreasing agent Substances 0.000 description 1
- 238000005237 degreasing agent Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960004486 desoxycorticosterone acetate Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960004833 dexamethasone phosphate Drugs 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical class C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
- 229960001912 dicoumarol Drugs 0.000 description 1
- HIZKPJUTKKJDGA-UHFFFAOYSA-N dicumarol Natural products O=C1OC2=CC=CC=C2C(=O)C1CC1C(=O)C2=CC=CC=C2OC1=O HIZKPJUTKKJDGA-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FVCOIAYSJZGECG-UHFFFAOYSA-N diethylhydroxylamine Chemical compound CCN(O)CC FVCOIAYSJZGECG-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 229960002124 diflorasone diacetate Drugs 0.000 description 1
- BOBLHFUVNSFZPJ-JOYXJVLSSA-N diflorasone diacetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)COC(C)=O)(OC(C)=O)[C@@]2(C)C[C@@H]1O BOBLHFUVNSFZPJ-JOYXJVLSSA-N 0.000 description 1
- 229960003970 diflucortolone valerate Drugs 0.000 description 1
- BZCOSCNPHJNQBP-OWOJBTEDSA-N dihydroxyfumaric acid Chemical compound OC(=O)C(\O)=C(/O)C(O)=O BZCOSCNPHJNQBP-OWOJBTEDSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004082 doxycycline hydrochloride Drugs 0.000 description 1
- 229960000385 dyclonine Drugs 0.000 description 1
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229960000655 ensulizole Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 229960003203 erythromycin estolate Drugs 0.000 description 1
- AWMFUEJKWXESNL-JZBHMOKNSA-N erythromycin estolate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(=O)CC)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AWMFUEJKWXESNL-JZBHMOKNSA-N 0.000 description 1
- 229960004142 erythromycin stearate Drugs 0.000 description 1
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 229960001618 ethambutol hydrochloride Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940042902 flumethasone pivalate Drugs 0.000 description 1
- JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960003973 fluocortolone Drugs 0.000 description 1
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229960003238 fluprednidene Drugs 0.000 description 1
- YVHXHNGGPURVOS-SBTDHBFYSA-N fluprednidene Chemical group O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](C(=C)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 YVHXHNGGPURVOS-SBTDHBFYSA-N 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 description 1
- 229940038487 grape extract Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- LIIALPBMIOVAHH-UHFFFAOYSA-N herniarin Chemical compound C1=CC(=O)OC2=CC(OC)=CC=C21 LIIALPBMIOVAHH-UHFFFAOYSA-N 0.000 description 1
- JHGVLAHJJNKSAW-UHFFFAOYSA-N herniarin Natural products C1CC(=O)OC2=CC(OC)=CC=C21 JHGVLAHJJNKSAW-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 229960001715 hexamidine isethionate Drugs 0.000 description 1
- TZMQHOJDDMFGQX-UHFFFAOYSA-N hexane-1,1,1-triol Chemical compound CCCCCC(O)(O)O TZMQHOJDDMFGQX-UHFFFAOYSA-N 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- 229960003331 hydrocortisone cypionate Drugs 0.000 description 1
- 229960000631 hydrocortisone valerate Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 150000005165 hydroxybenzoic acids Chemical class 0.000 description 1
- CFUQBFQTFMOZBK-QUCCMNQESA-N ibazocine Chemical compound C12=CC(O)=CC=C2C[C@H]2N(CC=C(C)C)CC[C@]1(C)C2(C)C CFUQBFQTFMOZBK-QUCCMNQESA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229940102398 methyl anthranilate Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- ZLQJVGSVJRBUNL-UHFFFAOYSA-N methylumbelliferone Natural products C1=C(O)C=C2OC(=O)C(C)=CC2=C1 ZLQJVGSVJRBUNL-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960002395 metronidazole hydrochloride Drugs 0.000 description 1
- FPTPAIQTXYFGJC-UHFFFAOYSA-N metronidazole hydrochloride Chemical compound Cl.CC1=NC=C([N+]([O-])=O)N1CCO FPTPAIQTXYFGJC-UHFFFAOYSA-N 0.000 description 1
- 229930184430 mimosol Natural products 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960002421 minocycline hydrochloride Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- 229960004832 netilmicin sulfate Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000017524 noni Nutrition 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- YBGZDTIWKVFICR-UHFFFAOYSA-N octinoxate Chemical compound CCCCC(CC)COC(=O)C=CC1=CC=C(OC)C=C1 YBGZDTIWKVFICR-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- FJCFFCXMEXZEIM-UHFFFAOYSA-N oxiniacic acid Chemical compound OC(=O)C1=CC=C[N+]([O-])=C1 FJCFFCXMEXZEIM-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229960004368 oxytetracycline hydrochloride Drugs 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 150000002948 pantothenic acids Chemical class 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229960002858 paramethasone Drugs 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- 229960005065 paromomycin sulfate Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 108010069653 peptide E (adrenal medulla) Proteins 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940117953 phenylisothiocyanate Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 150000003077 polyols Chemical group 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 150000004609 retinol derivatives Chemical class 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- XGRLSUFHELJJAB-JGSYTFBMSA-M sodium;[(2r)-2-hydroxy-3-[(z)-octadec-9-enoyl]oxypropyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)([O-])=O XGRLSUFHELJJAB-JGSYTFBMSA-M 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000007725 thermal activation Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960004477 tobramycin sulfate Drugs 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
- A45D34/00—Containers or accessories specially adapted for handling liquid toiletry or cosmetic substances, e.g. perfumes
- A45D34/04—Appliances specially adapted for applying liquid, e.g. using roller or ball
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
- A45D40/00—Casings or accessories specially adapted for storing or handling solid or pasty toiletry or cosmetic substances, e.g. shaving soaps or lipsticks
- A45D40/26—Appliances specially adapted for applying pasty paint, e.g. using roller, using a ball
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
- A61F7/03—Compresses or poultices for effecting heating or cooling thermophore, i.e. self-heating, e.g. using a chemical reaction
- A61F7/032—Compresses or poultices for effecting heating or cooling thermophore, i.e. self-heating, e.g. using a chemical reaction using oxygen from the air, e.g. pocket-stoves
- A61F7/034—Flameless
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
- A45D2200/00—Details not otherwise provided for in A45D
- A45D2200/10—Details of applicators
- A45D2200/1009—Applicators comprising a pad, tissue, sponge, or the like
- A45D2200/1018—Applicators comprising a pad, tissue, sponge, or the like comprising a pad, i.e. a cushion-like mass of soft material, with or without gripping means
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
- A45D2200/00—Details not otherwise provided for in A45D
- A45D2200/10—Details of applicators
- A45D2200/1009—Applicators comprising a pad, tissue, sponge, or the like
- A45D2200/1036—Applicators comprising a pad, tissue, sponge, or the like containing a cosmetic substance, e.g. impregnated with liquid or containing a soluble solid substance
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
- A45D2200/00—Details not otherwise provided for in A45D
- A45D2200/10—Details of applicators
- A45D2200/1054—Abrasive cosmetic skin peeling or scrubbing
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45D—HAIRDRESSING OR SHAVING EQUIPMENT; EQUIPMENT FOR COSMETICS OR COSMETIC TREATMENTS, e.g. FOR MANICURING OR PEDICURING
- A45D2200/00—Details not otherwise provided for in A45D
- A45D2200/15—Temperature
- A45D2200/155—Heating or cooling means, i.e. for storing or applying cosmetic products at a predetermined temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0001—Body part
- A61F2007/0002—Head or parts thereof
- A61F2007/0003—Face
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0001—Body part
- A61F2007/0029—Arm or parts thereof
- A61F2007/0036—Hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0001—Body part
- A61F2007/0029—Arm or parts thereof
- A61F2007/0037—Finger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0001—Body part
- A61F2007/0039—Leg or parts thereof
- A61F2007/0045—Foot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F2007/0001—Body part
- A61F2007/0052—Body part for treatment of skin or hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
- A61F2007/0244—Compresses or poultices for effecting heating or cooling with layers
- A61F2007/0258—Compresses or poultices for effecting heating or cooling with layers with a fluid permeable layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
- A61F2007/0261—Compresses or poultices for effecting heating or cooling medicated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/02—Compresses or poultices for effecting heating or cooling
- A61F2007/0261—Compresses or poultices for effecting heating or cooling medicated
- A61F2007/0263—Compresses or poultices for effecting heating or cooling medicated made of a substance with therapeutic action, e.g. copper or silver
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/24—Thermal properties
- A61K2800/242—Exothermic; Self-heating; Heating sensation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
- Medicinal Preparation (AREA)
Abstract
提供了一种化妆垫,所述化妆垫具有由非织造材料构成的顶层、以允许通过底层通风的方式构成的底层以及在顶层和底层之间的至少一个加热元件;和使用化妆垫和其中的化妆剂的方法。还提供了一种将化妆剂施加到受试者的皮肤、毛发、手、足或脸的系统。
Description
发明领域
本公开主要涉及用于提供多层垫的方法和系统,更具体地讲,涉及用于化妆或皮肤病学用途的多层垫。
发明背景
市场上现有的个人护理垫或小袋被设计为可在人皮肤上施加的施涂器或载体/制剂。例如,可在市场上买到面部清洁垫或枕。作为另一个实例,旅行尺寸或单剂量的个人护理制剂也可在市场上获得。然而,现今可用的产品不能在一个方便的包装中兼有将制剂储存和施加到皮肤的益处。此外,现今的产品在这样的设计和应用中不包括剥落和自加热元件。
发明概述
本文的实施方案提供了化妆垫以及使用化妆垫的方法。化妆垫包括由非织造材料构成的顶层、以允许通过底层通风的方式构成的底层以及在顶层和底层之间的至少一个加热元件。至少一个加热元件为放热加热源,并且通过使放热加热源暴露于空气而被启动。
化妆垫可进一步包括在顶层和底层之间的空气扩散层、在制剂顶层和制剂底层之间具有一种或多种产品的制剂层。一种或多种产品作为乳剂、凝胶剂、洗剂、乳膏剂、浆液或混悬剂存在。化妆垫在密封的包装内。化妆垫的底层包括一个或多个用于通风的口,并且底层进一步包括用于通风的透气材料。至少一个加热元件为单阶段或双阶段加热元件。化妆垫还包括在顶层和底层之间的指袋。一种或多种产品包含化妆剂或皮肤病学试剂,并且可以为肽、小分子、蛋白质、植物或水果提取物、维生素、油、有机油、蛋白质或其混合物。
本发明提供了一种施加一种或多种化妆品的方法。该方法包括通过将一个或多个手指插入化妆垫的指袋来将化妆垫施加到皮肤的一个或多个区域。本发明还公开了一种使用化妆垫的方法,其中所述方法包括打开化妆垫,将至少一个手指滑入化妆垫,并释放在化妆垫中容纳的制剂,其中该制剂包含一种或多种化妆剂或皮肤病学试剂,并且化妆垫以有效量施加到皮肤、身体或毛发的区域中。
本发明还提供了一种用化妆垫将化妆剂或皮肤病学试剂施加到受试者的皮肤、手、足、毛发或脸的系统。化妆垫附接到装置或施涂器,并且在化妆垫内容纳至少一种包含化妆剂或皮肤病学试剂的制剂。该系统可以为手治疗或足治疗系统。
附图简述
图1A显示根据本文的一个实施方案的化妆垫的皮肤接触侧;
图1B显示图1A中所示化妆垫的通风侧;
图1C显示用于图1B中所示皮肤化妆垫的通风侧的通风的示例性布置。
图2A显示图1A和图1B的化妆垫的分解图;
图2B显示图2A的层C的分解图;
图3显示根据本文的另一个实施方案的示例性化妆垫;
图4显示根据一个实施方案的化妆垫的横截面图,该图描绘了在化妆垫内容纳的自加热机制的示例性示意图;
图5A显示具有暴露的加热层的化妆垫;
图5B显示供选示例性自加热化妆垫;
图6显示根据一个实施方案的化妆垫的皮肤接触侧;
图7显示根据一个实施方案不具有空气扩散层的化妆垫的横截面图;
图8A显示图6和7的化妆垫(无空气扩散层的施涂器)在90秒初始加热后,随后在皮肤上摩擦60秒后在垫袋中具有手指的热图像;
图8B显示图8A的化妆施涂器在另外30秒后在垫袋中仍具有手指的热图像;
图8C显示图8B的化妆施涂器在另外30秒后(在图8A的热图像后60秒)在垫袋中仍具有手指的热图像;
图8D显示图8C的化妆施涂器在另外60秒后(在图8A的热图像后2分钟)在垫袋中仍具有手指的热图像;
图8E显示图8D的化妆施涂器在另外60秒后(在图8A的热图像后3分钟)在垫袋中仍具有手指的热图像;
图9A显示图8E的化妆施涂器在从垫袋移出手指后30秒的热图像;
图9B显示图9A的化妆施涂器在另外30秒后(在从垫袋移出手指后总共60秒)的热图像;
图9C显示图9B的化妆施涂器在另外30秒后(在从垫袋移出手指后总共90秒)的热图像;
图10显示根据一个实施方案具有空气扩散层的化妆垫的横截面图;
图11A显示图11的化妆垫(具有空气扩散层的施涂器)在90秒初始加热后,随后在皮肤上摩擦60秒后在垫袋中具有手指的热图像;
图11B显示图12A的化妆垫在另外30秒后在垫袋中具有手指的热图像;
图11C显示图12B的化妆垫在另外30秒后(在图12A的热图像后60秒)在垫袋中仍具有手指的热图像;
图11D显示图12C的化妆垫在另外60秒后(在图12A的热图像后总共2分钟)在垫袋中仍具有手指的热图像;
图11E显示图12D的化妆垫在另外60秒后(在图12A的热图像后总共3分钟)在垫袋中仍具有手指的热图像;
图12显示具有空气扩散层的化妆垫和不具有空气扩散层的化妆垫的加热曲线图;
图13显示根据一个实施方案的单阶段加热化妆垫的加热曲线图;
图14显示根据另一个实施方案的二阶段加热化妆垫的加热曲线图;
图15A显示根据一个实施方案的用于拾取化妆垫的示例性施涂器;
图15B显示用于化妆垫的施涂器的另一个示例性实施方案;
图16显示用于化妆垫的示例性棒施涂器;
图17显示用于化妆垫的示例性清洁装置;
图18显示示例性手治疗系统;并且
图19显示示例性足治疗系统。
发明详述
为了帮助理解本公开,下面定义了几个术语。本文定义的术语具有与本公开相关的领域的普通技术人员通常理解的含义。诸如“一个”、“一个”和“该”之类的词语不是要仅指单数实体,而是包括一般类别,其具体实例可用于说明。本文中的术语用于描述本公开的具体实施方案,但除了权利要求中概述的外,它们的使用不限制本公开。
本文所用“化妆剂”是指适合在哺乳动物角质组织上局部施加的化妆剂。化妆剂可以为帮助清洁或增强或保护受试者的皮肤、身体或毛发的外观(例如,颜色、质感、外表、感觉等)或气味的物质。化妆剂可改变皮肤或毛发的底层结构。
“受试者”指任何哺乳动物,优选为人。
本文所用术语“局部”是指在皮肤上施用一种或多种剂(例如,化妆品、维生素等)。
“透皮”是指一种剂(例如化妆剂、皮肤病学试剂、维生素等)通过皮肤递送(例如,使得至少一部分分子群到达皮肤的底层)。
除了在操作和比较性实施例外,或者另外明确指明,本描述中所有表示物质的量或比或反应条件、物质的物理性质和/或使用的数字均应理解为受词语“约”修饰。除非另外说明,所有量均表示为最终化妆剂的重量百分数。
本公开的实施方案提供了一种包括袋的自加热、活动式化妆垫。袋可预装有包含化妆剂或皮肤病学试剂的治疗产品。化妆剂或皮肤病学试剂可作为制剂存在。
在本公开的一个方面,化妆垫用剥落基材和自加热源构成,以增强疗效,并提供与常规护肤产品相比更快的效果。在一些实施方案中,垫可提供剥落益处。在其它实施方案中,垫可提供清洁、皮肤增亮、增艳或增白有益效果。化妆垫可用作皮肤、身体或毛发治疗系统。
本文提供了独特的皮肤护理系统,该系统包括作为单剂量用皮肤接触层构成的垫、具有包含化妆剂或皮肤病学试剂的制剂的治疗产品的预装隔室和自加热源。自加热源可以为任何以下类型之一:空气启动、水-无机盐混合物、水-多元醇混合物或电池供电的加热纸/基材。在一个实施方案中,系统可包括多于一个的预装隔室,并因此分别包括多于一种的制剂。系统还包括附接到垫的装置或施涂器。
本文提供了一种用于施加一种或多种包含化妆剂或皮肤病学试剂的制剂的方法。方法包括施加化妆垫,化妆垫具有由非织造材料构成的顶层、以允许通过底层通风的方式构成的底层以及在顶层和底层之间的至少一个加热元件。本发明还公开了一种使用化妆垫的方法,其中所述方法包括打开化妆垫,将至少一个手指滑入化妆垫,并释放在化妆垫中容纳的制剂,其中该制剂包含一种或多种化妆剂或皮肤病学试剂,并且化妆垫以有效量施加到皮肤、身体或毛发的区域中。
在实施方案中,在化妆垫内容纳的制剂可用于增白、增亮、抗衰老、痤疮、光滑、保湿、色素沉着、脱毛(去发)、脂肪团、妊娠纹、蜘蛛静脉、头皮治疗、毛发生长和对脸、身体或毛发的其它化妆或皮肤病学益处。在具体实施方案中,治疗产品作为单独或组合或在混合物中包含化妆剂、皮肤填充剂、肽、维生素、小分子、大分子、蛋白质、生物活性物质的制剂存在。制剂的所有形式均涵盖于本公开的范围内,包括可用于施加这样的化妆剂或皮肤病学试剂的包封、未包封或浸渍形式,并且可以为乳剂、凝胶剂、洗剂、乳膏剂、浆液或混悬剂的形式。
图1A显示根据本文的实施方案的化妆垫100的皮肤接触侧和化妆垫100的俯视图。化妆垫包括顶层、底层以及在顶层和底层之间的至少一个加热元件。皮肤接触侧可由非织造材料或任何其它合适的基材构成。在需要剥落的实施方案中,该材料可以为剥落基材,例如棉、羊毛、合成纤维和/或天然纤维或任何合适的材料。在需要皮肤光滑的实施方案中,材料可以为适合这样的用途的基材。在需要清洁的实施方案中,材料可以为适合这样的用途的基材。在需要化妆的实施方案中,材料可以为适合这样的用途的基材。示例性材料包括但不限于熔点在约80℃至约300℃范围的PP、聚对苯二甲酸乙二酯(PET)或PE非织造材料。在一些实施方案中,材料的厚度在约1毫米(mm)至10厘米(cm)的范围内,并且相对密度在0.01克/厘米3(g/cm3)至20g/cm3的范围内。
图1B显示包括化妆垫100的通风层A的通风侧或底视图。通风侧可包括具有通风切口的薄膜,如图1C中所示。在供选的实施方案中,化妆垫的通风侧可由透气和空气透过材料(例如网眼)构成,以允许适当的通风和足够的空气流动,而没有切口或其它通风口。在一些实施方案中,化妆垫的通风侧涂覆有适当聚合物或共聚物。示例性涂层包括乙二醇二乙酸酯、乙烯-乙酸乙烯酯、乙酸乙烯酯。在实施方案中,化妆垫的通风侧可由熔点在约80℃至约600℃范围的材料制成。示例性材料包括但不限于PP、聚对苯二甲酸乙二酯(PET)或PE非织造材料。在一些实施方案中,材料的厚度在约1毫米(mm)至约1厘米(cm)的范围内,并且相对密度在约0.01克/厘米3(g/cm3)至约20g/cm3的范围内。在一些实施方案中,可使材料着色。在一个优选的实施方案中,通风侧可具有很多通风口,如图1C中所示。这样的口可具有相同或不同的尺寸。
图1C显示存在于皮肤化妆垫100的通风层A中的通风口的示例性布置(即,底视图)。如图所示,通风层上通风口的数量、形状、尺寸和布置可以变化。在一些实施方案中,可使口着色。在其它实施方案中,可使口纹理化。在底层A(201)和层E(203)之间存在指袋。
图1D显示化妆垫100的示例性外视图。皮肤化妆垫100容纳在湿气阻挡袋层G中。湿气阻挡袋层使水分和空气与化妆垫100隔开。在一个实施方案中,层G由层压聚酯箔、聚乙烯或聚酯制成。
图2A显示根据本文的一个实施方案的化妆垫的各个层的分解图。
如图2A中所示,层A为通风层201,在一些实施方案中,通风层201可包括通风口202。如前提到,通风层201可由薄膜材料构成,或者可以涂覆。该层还用于提供分层材料,以产生袋,用于在使用或施加期间将手指插入垫并固定。基于垫的所需美感和产品设计,可选择刚性或柔软材料。用于薄膜层的示例性合适材料为具有铝的聚丙烯(PP)和聚乙烯(PE)薄膜,例如,可得自Amcor的Ceramis®。或者,通风层201可由自然通风材料(例如网)构成,以允许空气流动而没有特定的切口。在一些实施方案中,通风层A可用薄膜材料构成。在一些实施方案中,可用例如乙二醇二乙酸酯、乙烯-乙酸乙烯酯、乙酸乙烯酯等涂覆材料。在一些实施方案中,层A的厚度在约0.1毫米(mm)至约1厘米(cm)的范围内,重量在约0.1克/米2 (g/m2)至约200g/m2的范围内,并且熔点在约100℃至约300℃的范围内。
层E用作空气扩散层203、流通层或隔离层。空气扩散层203可由例如但不限于PP、聚对苯二甲酸乙二酯(PET)或PE非织造材料构成,这些材料的厚度在约0.1毫米(mm)至约1厘米(cm)的范围内,重量在约0.1克/米2 (g/m2)至约200g/m2的范围内,并且熔点在约100℃至约300℃的范围内。例如,非织造材料可得自Fibertex®。空气扩散层203存在于化妆垫的底层和化妆垫的顶层之间。具体地讲,空气扩散层204存在于化妆垫的底层和加热层204之间。
层204,也显示为层H,为具有至少一个加热元件的加热层,并且包含层H1、H2和H3。加热层204进一步在下面图2B中描绘,图2B显示了层H的组件H1、H2和H3。加热层204的组件H1、H2和H3用适当的密封密封在一起,例如热密封(即,用加热来密封层)。在一些实施方案中,可包括多于三个的组件。在一些实施方案中,可包括二个或甚至一个组件。所有这样的组合均被认为在本公开的范围内。
根据一个示例性实施方案,H1可由透气、柔性和空气透过材料构成,例如聚烯烃薄膜、PP、聚对苯二甲酸乙二酯(PET)或PE非织造材料。H2为加热引擎,可用例如碳、锌、PTFG、纤维素、水和盐之类的元件构造。可在本文化妆垫中使用的示例性加热元件为Exothermix®加热器,该加热器可从Rechargeable Battery Corporation商购获得。H3可由任何透气并提供通风和空气流通的材料制成,例如非织造材料、聚烯烃薄膜、PP、聚对苯二甲酸乙二酯(PET)或PE非织造材料。
根据本公开的一个实施方案,可设想化妆垫100包括至少一个加热元件204。在另一个实施方案中,化妆垫100可包括多于一个的加热元件204。在包括多于一个加热元件的实施方案中,可设想这样的加热元件以任何方式布置,例如,重叠、不重叠、部分重叠而其它部分不重叠等。加热元件可提供单阶段加热或双阶段加热。
加热元件204可产生约5秒至约5小时的热量。在实施方案中,加热元件可产生约5秒至约30分钟、约5秒至约45分钟、约5秒至约60分钟的热量。在一些实施方案中,加热元件可产生约35℃至约70℃的热量。在一个实施方案中,加热元件在约1秒至约30分钟内、在约1秒至约45分钟内产生约37℃至约50℃的热量。
在图2A中,层C, 207描绘了用于制剂的套,套为制剂层C, 207。制剂层C包括至少一个制剂顶层和至少一个制剂底层,其中制剂顶层和制剂底层二者均用热封、粘合剂或任何适当的密封机制密封在一起。根据包含化妆剂的制剂的形式和粘度,制剂可以自由形式容纳在室中或封闭层的内部,如D中所示,室或封闭层具有可在 C的制剂顶层上发现的一个或多个开口,开口构成制剂通过的手段。如果制剂为水性洗剂或者粘度更稀,则需要额外的制剂层确保制剂在室内均匀分布。如果制剂比轻洗剂稠,则该制剂可以为自由形式,并且可具有多于一个的开口,以能够在使用时穿过制剂层。在供选的实施方案中,可在层C中浸入制剂,使得可在制剂顶层或制剂底层或两者内发现该制剂。在一些实施方案中,可在层中容纳多种制剂。在特定实施方案中,可在层C中容纳或浸入多种制剂。
例如,制剂可容纳在制剂层中,制剂层由与用于空气扩散层203的那些相似的PET、PP或PE非织造材料构成,其厚度在1毫米(mm)至1厘米(cm)的范围内,重量在1g/m2至200g/m2的范围内。
拉条B显示于图2A中。拉条B用热封、粘合剂或适当的可撕开机制连接到层C(包括制剂顶层和制剂底层二者)。在通过拉扯或撕开机制释放拉条后,存在于层C(包括制剂顶层和制剂底层二者)的制剂将通过开口(存在于C的制剂顶层),因此,该制剂将变得可用。在一些实施方案中,可考虑多于一个的开口。如果制剂稠或为高粘性,则可用许多孔/开口允许制剂通过,并且可以任何方式布置这样的孔。可在层C(包括制剂顶层和制剂底层二者)中容纳包含化妆剂或皮肤病学试剂的任何制剂。制剂的粘度可在约1000厘泊至约1,000,000厘泊单位的范围内,包括其中的任何范围和子范围。
层F1为皮肤接触层208,该层可由PE、PET或PP非织造材料构成,例如,可从Sandler获得的Sawabond®非织造材料或任何其它合适的非织造材料。例如,皮肤接触层208可由在表面上具有丙烯酸点F2的木浆和聚酯的共混物构成,用于剥落、清洁、皮肤增白、皮肤光滑、去除粉刺、上妆等目的。用于皮肤接触层208的示例性材料为可从Fibertex Nonwovens获得的Aquadim®。
可在湿气阻挡袋层G内容纳整个化妆垫100。湿气阻挡袋层使水分和空气与化妆垫100隔开。在一个实施方案中,层G由层压聚酯箔或聚乙烯或聚酯制成。
应理解,在图2A的上下文中所示和所述的层的布置为示例性,并且这些层可以其它顺序布置,或者可包括附加层,或者排除某些层。
图2B显示根据本公开的一个实施方案加热层204的分解图。根据图2B中所示的实施方案,加热元件H包括层H1-H3,这些层可由非织造材料制成,一旦打开湿气阻挡袋层G(图2A中显示),该非织造材料就允许空气流通。在一些实施方案中,可考虑多于一个的热源。在一些实施方案中,加热层204可以为三个以上的层,并且层和加热元件的所有组合均被认为在本公开的范围内。
或者,在不同的实施方案中,图2B中所示的层H1和层H3可分别为阻挡层。层210和层212可用作湿气阻挡层或空气阻挡层,以防止加热元件的过早暴露和启动。阻挡层210和212之一或二者可以为由铝或任何其它合适材料构成的薄膜层。阻挡层210可包括拉条(205,在此未示出),当拉扯拉条时,其显露口(例如,口K,在此未示出),以暴露自加热机制,引发放热反应并允许热启动,例如,暴露于空气,用于空气启动的加热机制。此外,在供选的实施方案中,层H2,包括加热元件211,位于阻挡层210和212之间。该供选实施方案也显示于图5B中。
加热元件211可包括至少一个自加热源,该自加热源可以为空气启动的加热源、水-无机盐混合物、水-多元醇混合物或电池供电的加热纸/基材。层210、211和212一起形成加热层204,并且这些层可提供为单个单元,以组装成为化妆垫100的一部分。
加热层204可包括比图2B中所示和所述更多或更少的组件。例如,加热层204可包括多个加热源,或者更少或更多的阻挡层。
图3显示根据本公开的一个实施方案的示例性化妆垫300。如图所示,通风层为301,在一些实施方案中通风层可包括通风口302。通风层301可由薄膜材料或非织造材料构成,并且可包括通风口302。在一种变型中,通风层可由透气/通风材料构成,以允许在化妆垫300内空气流动而没有特定的切口/口。层301还可用于产生袋,以在施加或使用期间将手指插入垫并固定。
用于该薄膜层的示例性合适材料为具有铝的聚丙烯(PP)和聚乙烯(PE)薄膜,例如,可得自Amcor的Ceramis®。层303用作空气扩散层、流通层或隔离层。空气扩散层303可由例如但不限于PP、PET或PE非织造材料构成,这些材料的厚度在1毫米(mm)至10厘米(cm)的范围内,重量在0.1克/米2 (g/m2)至200g/m2的范围内。例如,可使用得自Fibertex®的非织造材料。层304为加热层,该层包括自加热元件。可在本公开的化妆垫中使用的示例性自加热加热元件为放热性加热器,可从Rechargeable Battery Corporation商购获得的Exothermix®加热器。
层307为制剂层。制剂可以自由形式容纳于室中或具有用于制剂通过的装置的封闭层内,例如拉条305,它使口306暴露,以允许制剂/产品流过。在一些实施方案中,所述制剂/产品可以为水溶液、使用的软膏剂、乳膏剂、泡沫剂、乳状洗剂或营养性化妆水、软化化妆水、乳状液体、化妆用基质、香精、肥皂、清洁溶液、防晒乳膏或油、混悬剂、乳剂、凝胶剂、糊剂、洗剂、粉剂、包含表面活性剂的清洁液、油、粉剂、粉底、乳剂、粉底或蜡粉底或其组合。例如,制剂可容纳在由与用于空气扩散层203的那些相似的PP或PE非织造材料构成的层中,其厚度在1毫米(mm)至约1厘米(cm)的范围内,重量在1g/m2至约200g/m2的范围内。层308为皮肤接触层,该层可由PE或PP非织造材料构成,例如,可从Sandler获得的Sawabond®非织造材料或任何其它合适的非织造材料。化妆垫300可在气密的密封包装320中提供,当打开时,它允许空气流动通过化妆垫300的各个层,并启动放热的加热元件304。密封包装320将有利保持皮肤接触侧清洁卫生,直到消费者使用为止。密封包装320可由不透气的材料制成,以防止自加热元件304意外或过早启动。
图4显示化妆垫100的横截面图,该图描绘了在启动热源时在化妆垫100内容纳的自加热机制的示例性示意图。在所示的实施方案中,在加热层204中使用了空气启动的加热元件。如图所示,空气经通风层201上的通风口202通过空气扩散层203进入化妆垫100。在通风层201由透气材料制成的实施方案中,空气将自由地进入整个层201,而不需要口202。当空气经口206进入加热层204时,加热元件211被启动,从而加热化妆垫100和在制剂室207中存在的包含化妆剂的制剂。随着从密封包装320移出化妆垫300时启动自加热元件304,图3中所示的化妆垫300发生类似作用。
图5A显示具有在皮肤接触层208下暴露的加热层204的化妆垫100。
图5B显示具有拉条机制205的供选示例性实施方案,拉条机制205用于启动加热层204的自加热机制。
图6显示根据一个实施方案的化妆垫的皮肤接触侧。如图所示,如果化妆垫100或化妆垫300要用手指手动施加、清洁、皮肤增艳、增亮、光滑、剥落,仅举几个例子。化妆垫可提供有袋,以容纳一个或多个手指。
化妆垫100或300可具有任何形状或尺寸,包括卵形、椭圆形、心形、锥形、圆形、正方形、矩形或任何其它可能的形状,并且可具有适用于所需功能和用途的包括针对眼、脸,身体或毛发应用的任何尺寸。
本公开的另一个方面涉及一种包括本文所述化妆垫的手治疗或足治疗系统。化妆垫和化妆剂中的空气启动自加热技术提供长期的温度控制,同时促进输送化妆剂。用预装的治疗制剂构造的用于手和/或足的这样的治疗系统,包括至少一个自容纳和自启动的加热源,提高了治疗的功效。本文所述的系统可针对一次使用,并且可在活动中使用。
图18显示了包括化妆垫的手套的实施方案。如图中所示,层E为空气扩散层203,并且存在于手套的顶部和底部。层F(即皮肤接触层(208))和层A(即通风层(202))不存在。
类似地,图19显示了包括化妆垫的袜的实施方案。如图中所示,层E为空气扩散层203,并且存在于袜的顶部和底部。层F(即皮肤接触层(208))和层A(即通风层(202))不存在。
实验
为了证明在具有空气扩散层的实施方案与不具有空气扩散层的实施方案之间的加热机制的加热曲线差异,如下所述进行实验。
图7显示根据一个实施方案不具有空气扩散层的化妆垫700的横截面图。如该实施方案中所示,化妆垫700在一侧(例如,顶侧)上包括通风层701。通风层由透气材料构成。化妆垫700还包括类似于图2A和2B中所示加热层204的加热层704。化妆垫700还包括制剂层707,该层可以为制剂室或袋。制剂层容纳包含化妆剂的治疗产品制剂。化妆垫700还在底侧上具有皮肤接触层708。在所示的实施方案中提供了指袋720,以允许一个或多个手指插入袋720,如图6中所示。
为了进行实验,用包含化妆剂的制剂填充制剂层707,并启动加热元件704。用数字温度计(例如,可从E Omega获得的HH509)获取温度读数,数字温度计通过在皮肤上保持温度探针结合到受试者上的皮肤区域(“目标区域”)。也用热相机(例如,热相机FLIR A655scLens FOL25)拍摄热图像。将化妆垫700放在受试者的目标区域上,并且皮肤接触层708接触目标区域。允许化妆垫700加热九十(90)秒的初始加热时间。然后,对目标区域手动摩擦化妆垫700,并且制剂释放到皮肤上。获取目标区域的初始温度读数并记录。
热图像显示于图8A中,其中热点(较浅/白色区域)的温度为约45℃,冷点(较暗/灰色区域)的温度为约37℃,并且平均温度(白色方块内的区域)为约41℃。在皮肤上摩擦化妆垫三十(30)秒后获取另一个读数。其热图像显示于图8B中,图8B显示,热点(较浅/白色区域)的温度为约46℃,冷点(较暗/灰色区域)的温度为约37℃,并且平均温度为约40℃。在初始接触后在1分钟、2分钟和3分钟标记处获取另外的读数。如图8C中所示,在图8A的温度读数后1分钟,热点(较浅/白色区域)的温度为约47℃,冷点(较暗/灰色区域)的温度为约37℃,并且平均温度为约40℃。如图8D中所示,在图8A的温度读数后2分钟,热点(较浅/白色区域)的温度为约48℃,冷点(较暗/灰色区域)的温度为约37℃,并且平均温度为约38℃。如图8E中所示,在图8A的温度读数后3分钟,热点(较浅/白色区域)的温度为约48℃,冷点(较暗/灰色区域)的温度为约37℃,并且平均温度为约39℃。在袋720中保持手指下获取读数。
如图8A-8E中所示,化妆垫700的平均温度随时间降低,并且热点的尺寸随时间减小,因为袋720中的手指在没有空气扩散层下阻碍空气流到加热元件704。
图9A至9C显示在图8E中所示的热图像后在从袋720移出手指后化妆垫700的热图像。图9A显示在从袋720移出手指后30秒化妆垫700的热图像。如图所示,热点(较浅/白色区域)的温度为约51℃,冷点(较暗/灰色的区域)的温度为约39℃,并且平均温度(方块内的区域)为约43℃。
图9B显示在从袋720移出手指后1分钟标记处的化妆垫700的热图像。热点(较浅/白色区域)的温度为约54℃,冷点(较暗/灰色的区域)的温度为约40℃,并且平均温度为约46℃。
图9C显示在从袋720移出手指后90秒化妆垫700的热图像。热点(较浅/白色区域)的温度为约59℃,冷点(较暗/灰色的区域)的温度为约43℃,并且平均温度为约51℃。
如图9A-9C所示,在从袋720移出手指,从而允许空气自由流到加热元件704后,化妆垫700的平均温度随时间升高,并且热点面积随时间增加。
图10显示根据本公开的一个实施方案具有空气扩散层1003的化妆垫1000的横截面图。所示的空气扩散层1003由PP、PET或PE非织造材料构成。与以上图7中所述实施方案的实验设置类似,用数字温度计(例如,可从E Omega获得的HH509)获取温度读数,数字温度计通过在皮肤上保持温度探针结合到受试者上的皮肤目标区域。也用热相机(例如,热相机FLIR A655sc Lens FOL25)拍摄热图像。化妆垫1000包括在制剂层1004内包含化妆剂的制剂,并且手指可放在袋1020内,用于手动施加化妆垫1000。将化妆垫1000放在受试者上的目标区域上,并且皮肤接触层1008接触目标区域。允许化妆垫1000加热九十(90)秒的初始加热时间。然后,对目标区域手动摩擦化妆垫1000,并且制剂释放到皮肤上。获取目标区域的初始温度读数并记录。
热图像显示于图11A中,其中热点(较浅/白色区域)的温度为约48℃,冷点(较暗/灰色区域)的温度为约41℃,并且平均温度(白色方块内的区域)为约48℃。在皮肤上摩擦化妆垫三十(30)秒后获取另一个读数。热图像显示于图11B中,图11B显示,热点(较浅/白色区域)的温度为约62℃,冷点(较暗/灰色区域)的温度为约47℃,并且平均温度为约49.5℃。在初始接触后在1分钟、2分钟和3分钟标记处获取另外的读数。
如图11C中所示,在图11A的温度读数后1分钟,热点(较浅/白色区域)的温度为约62℃,冷点(较暗/灰色区域)的温度为约47℃,并且平均温度为约50℃。如图11D中所示,在图11A的温度读数后2分钟,热点(较浅/白色区域)的温度为约64℃,冷点(较暗/灰色区域)的温度为约47℃,并且平均温度为约53℃。如图11E中所示,在图11A的温度读数后3分钟,热点(较浅/白色区域)的温度为约67℃,冷点(较暗/灰色区域)的温度为约48℃,并且平均温度为约55℃。在袋1020中保持手指下获取读数。如图11A-11E中所示,化妆垫1000的平均温度随时间升高,并且热点的尺寸随时间增加,即使手指在袋1020中。这样,空气扩散层1003流通并促进空气在化妆垫1000内流动,这在手指表面和加热元件1004之间提供了必要的间距。该间距确保适当的空气流通,用于在加热器内实现不间断的自加热反应功能,以在30秒至90分钟范围的施加时间期间产生连续不断的加热。
图12显示具有和不具有空气扩散层的化妆垫的温度曲线图。组成温度曲线的温度读数用热耦合测量,并显示于以下表1中。所示读数为通过将热电偶(例如E OMEGA HH509仪表热电偶温度探头)用带绑到受试者手背上的一块皮肤上获得的实际皮肤温度测量值。在通过去掉或破坏外袋或外层的密封而初始启动加热器后,使加热器加热约1分钟的初始加热时间。然后在固定热电偶(例如,以前后来回运动的方式用带子横捆)的这块皮肤上摩擦化妆垫。然后以1分钟间隔测量和记录温度5分钟。黑色实线表示不具有空气扩散层的化妆垫的温度读数,而灰色虚线表示具有空气扩散层的化妆垫的温度读数。如曲线图和以下表1中所示,没有空气扩散层的化妆垫的温度在一分钟后持续降低。具有空气扩散层的化妆垫的温度在热启动后的初始读数和热启动后五分钟之间保持相对一致。
表1:温度读数
根据一些实施方案,可能希望具有在单个阶段加热的化妆垫,例如,使用单个加热源。图13显示根据一个实施方案单阶段加热化妆垫的加热曲线图。如图13中所示,单阶段加热袋的热输送响应和施加步骤如下:
步骤1:在通过拆下密封片,以暴露于空气并引发放热反应启动时,加热元件达到预定温度。加热器将封闭制剂的温度加热到所需的温度,例如约40℃;
步骤2:在将制剂加热到所需的温度后,受试者取下温热的化妆垫,在皮肤上按摩约1-5分钟,以给予皮肤治疗;和
步骤3:在治疗后,加热元件的放热反应停止,使用者可安全地丢弃化妆垫。
单阶段加热需要约3至7分钟或更长的时间才能将制剂加热到40℃或更高的温度。此外,单阶段加热方法在初始启动后的整个使用期间提供一个温度输出。
在其它实施方案中,可能希望化妆垫包括多于一个的加热阶段。图14显示根据本公开的一个实施方案双阶段加热化妆垫的加热曲线图。双阶段加热机制改变了自加热垫的整体性能以及最终受试者的治疗产品应用体验。加热元件分两个阶段输送热量,每个阶段提供不同的加热输出和定时间隔。下面参考图14描述示例性双阶段加热方法:
步骤1:在阶段A,制剂用一小阵强热加热达到目标温度,例如40℃,比利用单阶段加热方法更快。这可缩短步骤1期间受试者的初始等待时间,例如,通过将加热时间缩短到一分钟;
步骤2:在完成阶段A时,阶段B加热将继续提供足够的热量,以保持制剂的温度,同时避免高/强热和在使用期间皮肤/手指不适;
步骤3:在治疗应用结束,加热元件自行终止,且化妆垫冷却到室温。
双阶段加热有利地将治疗产品和制剂更快地初始加热到期望温度,并且潜在地用多个加热阶段对化妆垫的加热曲线提供更多控制。
在供选的实施方案中,化妆垫可包括多个加热阶段。例如,可包括第三或第四阶段的加热阶段,以在施加期间增加多阵热量。
使用/施加
根据本公开的一个方面,使用化妆垫的方法包括以下步骤:
步骤1:打开湿袋G,这启动化妆垫中存在的加热元件;
步骤2:等待约30秒至约5分钟,优选约1分钟至1分钟30秒;
步骤3:将至少一个手指滑到化妆垫的皮肤接触侧(201或301);
步骤4:拉扯如图2A中所示的条B,以释放制剂;
步骤5:在皮肤(包括身体、脸、前臂、身体、眼或眼睛周围的区域、头发等)上摩擦或施加化妆垫层208(或308)约30秒至约30分钟,以释放制剂。根据一个实施方案,可在皮肤上使用化妆垫约2分钟至约10分钟。
在各种实施方案中,可提供化妆垫与施涂器一起使用。例如出于卫生或安全目的,为了避免用手指施加/使用化妆垫,理想使用施涂器。例如,化妆垫可在一侧上包括带,用于在使用期间插入和固定一个或多个手指。在本领域中已知许多不同的施涂器或装置,并且所有这样的施涂器都包括在本公开的公开内容内。
图15A显示根据本公开的一个实施方案用于拾取化妆垫的示例性施涂器。可用施涂器1502拾取化妆垫1501,如图所示,例如,经由粘合机制或钩环紧固机制,例如可从Velcro®购得的那些。
图15B显示用于化妆垫的施涂器的另一个示例性实施方案。可用施涂器1503拾取化妆垫1501,如图所示。用于将化妆垫1501附接到施涂器1503的合适机制包括但不限于弱粘合剂、钩环紧固件等。
图16显示用于化妆垫的示例性棒施涂器。可用施涂器1602拾取化妆垫1601,如图所示。图17显示用于化妆垫1701的示例性清洁装置1702。化妆垫1701通过弱粘合机制、钩环紧固件等附接到清洁装置1702。
在化妆垫与施涂器或装置一起使用的实施方案中,通风层可以允许空气自由流动的方式构造,例如,化妆垫上的通风口不会被装置或施涂器堵塞。例如,施涂器可布置有与化妆垫上那些相对应的口,或者可布置有遍布整个施涂器的通风设计,以允许空气自由流动通过化妆垫的通风层。
制剂
根据本公开的实施方案,治疗产品包括化妆剂(包括肽、小分子、维生素、清洁剂、剥落剂、生物活性物质、有机酸,单独或以混合物、包封或未包封形式)和皮肤病学试剂的任何制剂。治疗产品的数量可共同制定。
在一些实施方案中,存在于制剂中的化妆剂可以清洁、剥落、光滑或修复受试者的皮肤、身体或毛发。在一个实施方案中,可在制剂套中存在一种治疗产品。然而,在其它实施方案中,可在多个各自的套中容纳多于一种的治疗产品,每个套具有不同的化妆或皮肤病学益处和用途,并且可在不同的释放时机以不同的速率启动和加热每种产品。化妆剂的所有这样的组合和变更都包括在本公开的公开内容内。
根据本公开的一个方面,可以将包含化妆剂的制剂施加到哺乳动物的角质组织、人的皮肤、脸或头发。包含化妆剂的制剂可具有各种形式。例如,这样形式的一些非限制实例包括溶液剂、混悬剂、洗剂、乳膏剂、凝胶剂、乳剂、混悬剂、调色剂、软膏剂、清洁剂、剥落剂、洗发液和毛发调理剂、糊剂、泡沫剂、粉剂、摩丝、剃须膏、水凝胶、成膜产品、面部和皮肤面膜等。
在一些实施方案中,存在于制剂中的化妆剂未包封。在一些其它实施方案中,将制剂中存在的化妆剂包封。此外,在特定的实施方案中,化妆剂可存在于层708中,或者化妆剂可浸入层707(顶层或底层)内,例如在层的孔间。
根据本公开的一个实施方案,包含化妆剂或皮肤病学试剂的制剂包括肽、小分子、大分子、蛋白质、维生素、清洁剂、剥落剂、生物活性物质、有机酸(包括透明质酸、单宁酸)、油、洗发剂、调理剂、护发剂、植物或水果提取物、天然产生剂,它们可单独或以混合物或组合形式、未包封或包封形式存在。
这些额外化妆剂或成分的非限制实例包括皮肤护理活性物质,例如肽(例如,Matrixyl(五肽)衍生物)、法呢醇、红没药醇、植烷三醇、甘油、尿素、胍(例如,氨基胍);维生素及其衍生物,例如抗坏血酸、维生素A(例如类视黄醇衍生物,例如棕榈酸视黄酯或丙酸视黄酯)、维生素E(例如生育酚乙酸酯)、维生素B3(例如烟酰胺)和维生素B5(例如泛醇)等及其混合物;防晒剂;抗痤疮药物(例如但不限于间苯二酚、水杨酸等);抗氧化剂(例如植物甾醇、硫辛酸);类黄酮(例如异黄酮、植物雌激素);皮肤缓和和愈合剂,例如但不限于芦荟提取物、尿囊素等;螯合剂和多价螯合剂;以及适合美感用途的剂,例如精油、香料、皮肤感觉剂、遮光剂、芳香族化合物(例如丁香油、薄荷醇、樟脑、桉树油和丁香酚)。
合适的羧酸共聚物、乳化剂、润肤剂和其它附加成分的非限制实例公开于1991年4月30日授予Ciotti等人的美国专利号5,011,681和1999年8月17日授予Oblong等人的美国专利号5,939,082,二者的全部内容通过引用结合到本文中。上述维生素B3化合物可作为以结晶形式保留在化妆剂中的重结晶结晶混入,或者作为部分增溶的结晶混入(即,一些晶体溶解,而另一些以结晶形式保留在化妆剂中)。
在化妆剂要与人角质组织(即皮肤、脸或毛发)接触的一个实施方案中,这些另外的组分应适合于施加到角质组织。即,当混入化妆剂时,它们适合与人角质组织接触,而没有过度的毒性、不相容性、不稳定性、过敏反应,并且在合理的科学判断范围内。
The CTFA Cosmetic Ingredient Handbook(CTFA化妆品成分手册), SecondEdition (1992)描述了皮肤护理行业中常用的多种非限制化妆品和药物成分,它们适用于本公开的化妆剂。这些成分种类的实例包括磨料、吸收剂、美感成分(例如香料、颜料、着色剂/着色剂、精油)、皮肤感觉剂、收敛剂等(例如丁香油、薄荷醇、樟脑、桉树油、丁香酚、乳酸薄荷酯、金缕梅馏出物)、抗粉刺剂、抗结块剂、消泡剂、抗微生物剂(例如,丁基氨基甲酸碘丙酯)、抗氧化剂、粘合剂、生物添加剂、缓冲剂、填充剂、螯合剂、化学添加剂、着色剂、化妆品收敛剂、化妆品杀生物剂、变性剂、药物收敛剂、外用止痛剂、有助于化妆剂的成膜性质和直接性的成膜剂或材料(例如聚合物)(例如二十碳烯和乙烯基吡咯烷酮的共聚物)、遮光剂、pH调节剂、推进剂、还原剂、多价螯合剂、皮肤漂白和增艳剂(例如氢醌、曲酸、抗坏血酸、抗坏血酸磷酸酯镁、抗坏血酸氨基葡萄糖)、皮肤调理剂(例如湿润剂,包括混杂型和堵塞型)、皮肤缓和和/或愈合剂(例如泛醇及衍生物(例如乙基泛醇)、芦荟、泛酸及其衍生物、尿囊素、红没药醇和甘草酸二钾)、皮肤治疗剂、增稠剂和维生素及其衍生物。
本公开的局部化妆剂可包含安全且有效量的法呢醇。法呢醇是一种天然产生的物质,据信该物质在角鲨烯和甾醇(尤其为胆甾醇)的生物合成中作为前体和/或中间体。法呢醇也涉及蛋白质修饰和调节(例如蛋白质的法呢基化),并且有对法呢醇有反应的细胞核受体。
化学上,法呢醇为[2E,6E]-3,7,11-三甲基-2,6,10-十二碳三烯-1-醇,并且如本文所用,“法呢醇”包括其异构体和互变异构体。法呢醇可商购获得,例如,以法呢醇(得自Dragoco, 10 Gordon Drive, Totowa, N.J.的异构体的混合物)和反式-反法呢醇(SigmaChemical Company, P.O. Box 14508, St. Louis, Mo.)的名义。
当存在于本公开的化妆剂时,化妆剂优选包含以化妆剂重量计约0.001%至约50%,更优选约0.01%至约20%,甚至更优选约0.1%至约15%,甚至更优选约0.1%至约10%,还更优选约0.5%至约5%,再更优选约1%至约5%。
本公开的局部化妆剂可包含安全且有效量的植烷三醇。植烷三醇为称为3,7,11,15-四甲基十六烷-1,2,3-三醇的化学品的常用名。植烷三醇可购自BASF(1609 BiddleAvenue, Whyandotte, Mich.)。例如,植烷三醇可用作蜘蛛血管/红斑修复剂、黑眼圈/眼浮肿修复剂、肤黄修复剂、下垂修复剂、止痒剂、皮肤增厚剂、毛孔减少剂、油/亮减轻剂、炎后色素沉着过度修复剂、伤口治疗剂、消脂剂,并调节皮肤质感,包括皱纹和细纹。
植烷三醇优选以化妆剂重量计约0.001%至约50%的量包含在本公开的化妆剂中,更优选约0.01%至约20%,甚至更优选约0.1%至约15%,甚至更优选约0.2%至约10%,还更优选约0.5%至约10%,还更优选约1%至约5%。
可将安全且有效量的脱皮活性物质加到本公开的化妆剂,更优选以化妆剂重量计约0.1%至约10%,甚至更优选约0.2%至约5%,还优选约0.5%至约4%。脱皮活性物质增大了本公开的皮肤外观益处。例如,脱皮活性物质倾向于改善皮肤的质感(例如,光滑度)。适用于本发明的一种脱皮系统包含巯基化合物和两性离子表面活性剂,并描述于授予Bissett的美国专利号5,681,852,所述专利通过引用结合到本文中。适用于本发明的另一种脱皮系统包含水杨酸和两性离子表面活性剂,并描述于授予Bissett的美国专利号5,652,228,所述专利通过引用结合到本文中。如这些申请中所述的两性离子表面活性剂也可用作本文的脱皮剂,其中鲸蜡基甜菜碱是特别优选的。
本公开的化妆剂可包含安全且有效量的一种或多种抗痤疮活性物质。有用抗痤疮活性物质的实例包括间苯二酚、硫、水杨酸、过氧化苯甲酰、红霉素、锌等。合适的抗痤疮活性物质的其它实例更详细描述于1997年3月4日授予McAtee等人的美国专利号5,607,980。
本公开的化妆剂可进一步包含安全且有效量的一种或多种抗皱活性物质或抗萎缩活性物质。适用于本公开的化妆剂的示例性抗皱/抗萎缩活性物质包括包含硫的D和L氨基酸及其衍生物和盐,特别为N-乙酰基衍生物,其优选实例为N-乙酰基-L-半胱氨酸;硫醇,例如乙硫醇;羟基酸(例如,α-羟基酸,例如乳酸和乙醇酸,或β-羟基酸,例如水杨酸和水杨酸衍生物,例如辛酰基衍生物)、植酸、硫辛酸;溶血磷脂酸、皮肤剥落剂(例如苯酚等)、维生素B3化合物和类视黄醇,它们提高了本公开的角质组织外观,尤其在调节角质组织状况中,例如皮肤状况。
本公开的化妆剂可包含安全且有效量的维生素B3化合物。维生素B3化合物对于调节皮肤状况特别有用。当维生素B3化合物存在于本公开的化妆剂时,化妆剂优选包含以化妆剂重量计约0.01%至约50%维生素B3化合物,更优选约0.1%至约10%,甚至更优选约0.5%至约10%,并且还更优选约1%至约5%,还更优选约2%至约5%。
前述维生素B3化合物的示例性衍生物包括烟酸酯,包括非血管舒张的烟酸酯(例如生育酚烟酸酯)、烟酰氨基酸、羧酸的烟醇酯、N-氧化烟酸和N-氧化烟酰胺。合适的维生素B3化合物的实例在本领域中是众所周知的,并且可从许多来源商购获得,例如,SigmaChemical Company(St. Louis, Mo.);ICN Biomedicals, Inc.(Irvin, Calif.)和Aldrich Chemical Company(Milwaukee, Wis.)。维生素化合物可作为基本纯物质包括在内,也可作为通过从天然(例如植物)源进行适当物理和/或化学分离而获得的提取物包括在内。
本公开的化妆剂还可包含类视黄醇。本文所用“类视黄醇”包括在皮肤中具有维生素A的生物活性的维生素A或类视黄醇化合物的所有天然和/或合成类似物,以及这些化合物的几何异构体和立体异构体。类视黄醇优选为视黄醇、视黄醇酯(例如视黄醇的C2 -C22烷基酯,包括棕榈酸视黄酯、乙酸视黄酯、丙酸视黄酯)、视黄醛和/或视黄酸(包括全反式视黄酸和/或13-顺-视黄酸),更优选视黄酸以外的类视黄醇。这些化合物在本领域是众所周知的,并且可从许多来源商购获得,例如Sigma Chemical Company(St. Louis, Mo.)和Boerhinger Mannheim(Indianapolis, Ind.)。可用于本文的其它类视黄醇描述于1987年6月30日授予Parish等人的美国专利号4,677,120;1989年12月5日授予Parish等人的美国专利号4,885,311;1991年9月17日授予Purcell等人的美国专利号5,049,584;1992年6月23日授予Purcell等人的美国专利号5,124,356;和1992年9月22日授予Purcell等人的美国专利号Reissue 34,075。其它合适的类视黄醇为生育酚-视黄酸酯[视黄酸的生育酚酯(反式或顺式-)、阿达帕林{6-[3-(1-金刚烷基)-4-甲氧基苯基]-2-萘甲酸}和他扎罗汀(6-[2-(4,4-二甲基二氢苯并噻喃-6-基)-乙炔基]烟酸乙酯)。优选的类视黄醇为视黄醇、棕榈酸视黄酯、乙酸视黄酯、丙酸视黄酯、视黄醛及其组合。类视黄醇可作为基本纯物质包括在内,也可作为通过从天然(例如植物)源进行适当物理和/或化学分离而获得的提取物包括在内。类视黄醇优选实质是纯的,更优选基本是纯的。本公开的化妆剂可包含安全且有效量的类视黄醇,使得所得的化妆剂安全且有效地用于调节角质组织状况,优选用于调节皮肤中的可见和/或触觉不连续性,更优选用于调节皮肤老化的体征,甚至更优选用于调节与皮肤老化相关的皮肤质感的可见和/或触觉不连续性。化妆剂优选包含从或约0.005%至或约2%、更优选0.01%至或约2%类视黄醇。视黄醇优选以从或约0.01%至或约0.15%的量使用;视黄醇酯优选以从或约0.01%至或约2%(例如约1%)的量使用;视黄酸优选以从或约0.01%至或约0.25%的量使用;生育酚-视黄酸酯、阿达帕林和他扎罗汀优选以从或约0.01%至或约2%的量使用。
当本公开的化妆剂同时包含类视黄醇和维生素B3化合物时,优选以上述量使用类视黄醇,并且优选以从或约0.1%至或约10%(更优选从或约2%至或约5%)的量使用维生素B3化合物。
本公开的化妆剂可包含安全且有效量的羟基酸或透明质酸或单宁酸。用于本公开的化妆剂的优选羟基酸包括水杨酸和水杨酸衍生物。当存在于本公开化妆剂时,透明质酸或水杨酸优选以约0.01%至约50%、更优选约0.1%至约20%、甚至更优选约0.1%至约10%、还更优选约0.5%至约5%且还更优选约0.5%至约2%的量使用。
肽包括但不限于二肽、三肽和四肽及其衍生物,可以安全且有效的量包含在本公开的化妆剂中。本文所用“肽”是指天然产生的肽和合成的肽二者。天然产生的和可商购的包含肽的化妆剂在本文中也是可用的。
用于本文的合适的二肽包括肌肽(β-ala-his)。用于本文的合适的三肽包括gly-his-lys、arg-lys-arg、his-gly-gly 。优选的三肽及其衍生物包括棕榈酰基-gly-his-lys,可作为Biopeptide CL.RTM.购买(100ppm的棕榈酰基-gly-his-lys,可从Sederma,France商购获得);Peptide CK(arg-lys-arg);Peptide CK+(ac-arg-lys-arg-NH.sub.2);和从Sigma(St.Louis, Mo.)作为lamin商业销售的his-gly-gly的铜衍生物。用于本文的合适的四肽包括Peptide E,arg-ser-arg-lys(SEQ ID NO:1)。
另外的肽选自棕榈酰基-gly-his-lys、β-ala-his、其衍生物及其组合。更优选另外的肽选自棕榈酰基-gly-his-lys、其衍生物及其组合。
在本发明的化妆剂中包含时,肽优选以化妆剂重量计约0.000001%至约10%的量包含在内,更优选约0.000001%至约0.1%,甚至更优选约0.00001%至约0.01%。在包括肽Carnosine.RTM.的某些实施方案中,化妆剂优选包含以化妆剂重量计约0.1%至约5%的这样的肽。在其中包括包含肽的化妆剂Biopeptide CL.RTM.的其它实施方案中,所得化妆剂优选包含以化妆剂重量计约0.1%至约10%的Biopeptide。
本公开的化妆剂可包含安全且有效量的抗氧化剂/自由基清除剂。抗氧化剂/自由基清除剂尤其可用于提供针对可能导致角质层剥落或质感变化增加的UV辐射以及针对可能导致皮肤损伤的其它环境因素的保护。
可将安全且有效量的抗氧化剂/自由基清除剂加到本公开的化妆剂,优选为化妆剂的约0.1%至约10%,更优选约1%至约5%。
可使用抗氧化剂/自由基清除剂,例如抗坏血酸(维生素C)及其盐、脂肪酸的抗坏血酸酯、抗坏血酸衍生物(例如抗坏血酸磷酸酯镁、抗坏血酸磷酸酯钠、抗坏血酸山梨酸酯)、生育酚(维生素E)、生育酚山梨酸酯、生育酚乙酸酯、生育酚的其它酯、丁基化羟基苯甲酸及其盐、6-羟基-2,5,7,8-四甲基二氢苯并吡喃-2-二甲酸(以商品名Trolox.RTM.商购获得)、没食子酸及其烷基酯(尤其没食子酸丙酯)、尿酸及其盐和烷基酯、山梨酸及其盐、硫辛酸、胺(例如N,N-二乙基羟胺、氨基胍)、巯基化合物(例如谷胱甘肽)、二羟基富马酸及其盐、氧脯氨酸赖氨酸盐、氧脯氨酸精氨酸盐、去甲二氢愈创木酸、生物类黄酮、姜黄素、赖氨酸、1蛋氨酸、脯氨酸、超氧化物歧化酶、水飞蓟素、茶提取物、葡萄皮/种子提取物、黑色素和迷迭香提取物。优选的抗氧化剂/自由基清除剂选自生育酚山梨酸酯和生育酚的其它酯,更优选生育酚山梨酸酯。例如,在1989年7月11日授予Donald L. Bissett、Rodney D. Bush和Ranjit Chatterjee的美国专利号4,847,071中描述了在局部化妆剂中且适用于本公开的生育酚山梨酸酯的使用。
本公开的化妆剂也可包含安全且有效量的螯合物或螯合剂。本文所用“螯合物”或“螯合剂”是指能够通过形成络合物从系统去除金属离子,使得金属离子可能不容易参与或催化化学反应的活性剂。包含螯合剂尤其可用于提供针对可能促使过度剥落或皮肤质感变化的UV辐射以及针对可能导致皮肤损伤的其它环境因素的保护。
可将安全且有效量的螯合剂加到本公开的化妆剂,优选为化妆剂的约0.1%至约10%,更优选约1%至约5%。可用于本文的示例性螯合剂公开于1996年1月30日授予Bissett等人的美国专利号5487884;1995年10月31日公布的Bush等人的国际公布号91/16035;和1995年10月31日公布的Bush等人的国际公布号91/16034。在化妆剂中有用的优选螯合剂为糠偶酰二肟、糠偶酰一肟及其衍生物。
本公开的化妆剂可任选包含类黄酮化合物。类黄酮广泛公开于美国专利号5,686,082和5,686,367,这两个专利均通过引用结合到本文中。适用于本公开的类黄酮为黄烷酮,选自未取代的黄烷酮、单取代的黄烷酮及其混合物;查耳酮,选自未取代的查耳酮、单取代的查耳酮、二取代的查耳酮、三取代的查耳酮及其混合物;黄酮,选自未取代的黄酮、单取代的黄酮、二取代的黄酮及其混合物;一种或多种异黄酮;香豆素,选自未取代的香豆素、单取代的香豆素、二取代的香豆素及其混合物;色酮,选自未取代的色酮、单取代的色酮、二取代的色酮及其混合物;一种或多种双香豆素;一种或多种色满酮;一种或多种色满醇;其异构体(例如顺/反异构体);及其混合物。本文所用术语“经取代的”是指这样的类黄酮,其中类黄酮的一个或多个氢原子已独立用羟基、C1-C8烷基、C1-C4烷氧基、O-糖苷等或这些取代基的混合取代。
合适的类黄酮的实例包括但不限于未取代的黄烷酮、单羟基黄烷酮(例如2-羟基黄烷酮、6-羟基黄烷酮、7-羟基黄烷酮等)、单烷氧基黄烷酮(例如5-甲氧基黄烷酮、6-甲氧基黄烷酮、7-甲氧基黄烷酮、4-甲氧基黄烷酮等)、未取代的查耳酮(尤其未取代的反-查尔酮)、单羟基查耳酮(例如2-羟基查耳酮、4-羟基查耳酮等)、二羟基查耳酮(例如2,4-二羟基查耳酮、2,4-二羟基查耳酮、2,2-二羟基查耳酮、2,3-二羟基查耳酮、2,5-二羟基查耳酮等)和三羟基查耳酮(例如2,3,4-三羟基查尔酮、4,2,4-三羟基查尔酮、2,2,4-三羟基查尔酮等)、未取代的黄酮、7,2-二羟基黄酮、3,4-二羟基萘黄酮、4-羟基黄酮、5,6-苯并黄酮和7,8-苯并黄酮、未取代的异黄酮、黄豆苷元(7,4-二羟基异黄酮)、5,7-二羟基-4-甲氧基异黄酮、大豆异黄酮(从大豆提取的混合物)、未取代的香豆素、4-羟基香豆素、7-羟基香豆素、6-羟基-4-甲基香豆素、未取代的色酮、3-甲酰基色酮、3-甲酰基-6-异丙基色酮、未取代的双香豆素、未取代的色满酮、未取代的色满醇及其混合物。
它们可以为合成材料,也可作为来自天然源(例如植物)的提取物获得。天然来源的材料也可进一步衍生化(例如,在从天然源提取后制备的酯或醚衍生物)。可用于本发明的类黄酮化合物可从许多来源商购获得,例如,Indofine Chemical Company, Inc.(Somerville, N.J.)、Steraloids, Inc.(Wilton, N.H.)和Aldrich Chemical Company,Inc. (Milwaukee, Wis.)。也可使用上述类黄酮化合物的混合物。
可将安全且有效量的消炎剂加到本公开的化妆剂,优选化妆剂的约0.1%至约10%,更优选约0.5%至约5%。消炎剂增强了本公开的皮肤外观有益效果,例如,这样的剂有助于更均匀和可接受的皮肤色调或颜色。要在化妆剂中使用的消炎剂的确切量将取决于所使用的特定消炎剂,因为这样的剂的效力变化很大。
可使用甾体类消炎剂,包括但不限于皮质甾类,例如氢化可的松、羟基曲安西龙、α-甲基地塞米松、磷酸地塞米松、丙酸倍氯米松、戊酸氯倍他索、地奈德、去氧美达松、醋酸去氧皮质酮、地塞米松、二氯松、双醋二氟拉松、戊酸二氟可龙、fluadrenolone、氟氯奈德、氟氢可的松、新戊酸氟米松、氟西奈德、醋酸氟轻松、氟可丁酯、氟可龙、醋酸氟泼尼定(fluprednylidene)、氟氢缩松、哈西奈德、醋酸氢化可的松、丁酸氢化可的松、甲泼尼龙、曲安奈德、可的松、可托多松、flucetonide、氟氢可的松、difluorosone diacetate、fluradrenolone、氟氢可的松、diflurosone diacetate、fluradrenolone acetonide、甲羟松、安西法尔(amcinafel)、安西非特、倍他米松及其余量的酯、氯泼尼松、醋酸氯泼尼松、clocortelone、clescinolone、二氯松、diflurprednate、氟氯奈德、氟尼缩松、氟米龙、氟培龙、氟泼尼龙、戊酸氢化可的松、环戊基丙酸氢化可的松、氢可他酯、甲泼尼松、帕拉米松、泼尼松龙、泼尼松、丙酸倍氯米松、曲安西龙及其混合物。优选使用的甾体类消炎药为氢化可的松。
可用于化妆剂的第二类消炎剂包括非甾体类消炎剂。该组包括的各种化合物为本领域的技术人员所熟悉。关于非甾体类消炎剂的化学结构、合成、副作用等的详细公开内容,可参考标准文本,包括Anti-inflammatory and Anti-Rheumatic Drugs(消炎和抗风湿药), K. D. Rainsford, Vol. I-III, CRC Press, Boca Raton, (1985)和Anti-inflammatory Agents, Chemistry and Pharmacology(消炎剂、化学和药理学), 1, R.A. Scherrer, et al., Academic Press, New York (1974)。
本公开的化妆剂也可包含安全且有效量的消脂剂。合适的剂可包括但不限于黄嘌呤化合物(例如咖啡因、单宁、茶碱、可可碱和氨茶碱)。
本公开的化妆剂也可包含安全且有效量的局部麻醉剂。局部麻醉药的实例包括苯佐卡因、利多卡因、布比卡因、氯普鲁卡因、地布卡因、依替卡因、甲哌卡因、丁卡因、达克罗宁、海克卡因、普鲁卡因、可卡因、氯胺酮、普莫卡因、苯酚及其药学上可接受的盐。
本公开的化妆剂可包含晒黑活性物质。存在时,化妆剂优选包含以化妆剂重量计约0.1%至约20%、更优选约2%至约7%且还更优选约3%至约6%的二羟丙酮作为人造晒黑活性物质。二羟丙酮,也称为DHA或1,3-二羟基-2-丙酮,为白色至灰白色结晶粉末。
该化合物可作为单体和二聚体的混合物存在,其中二聚体以固体结晶态为主。在加热或熔融时,二聚体断裂产生单体。二聚体形式向单体形式的这种转化也发生在水溶液中。也已知二羟丙酮在酸性pH值更稳定。参见,The Merck Index(默克索引), TenthEdition, entry 3167, p. 463 (1983)和“Dihydroxyacetone for Cosmetics”(用于化妆品的二羟丙酮), E. Merck Technical Bulletin, 03-304 110, 319 897, 180 588。
本公开的化妆剂可包含皮肤增艳剂。使用时,化妆剂优选包含以化妆剂重量计约0.1%至约10%、更优选约0.2%至约5%、还优选约0.5%至约2%的皮肤增艳剂。合适的皮肤增艳剂包括在本领域已知的那些,包括曲酸、熊果苷、抗坏血酸及其衍生物(例如抗坏血酸磷酸酯镁或抗坏血酸磷酸酯钠)和提取物(例如桑提取物、胎盘提取物)。适用于本文的皮肤增艳剂还包括Hillebrand名义的PCT公布号95/34280(对应于在1995年6月12日提交的PCT申请号U.S. Ser. No. 95/07432)和以Kvalnes、Mitchell A. DeLong、Barton J. Bradbury、Curtis B. Motley和John D. Carter的名义提交的同时待审美国申请序列号08/390,152(对应于9/8/95公布的PCT公布序列号95/23780)中所述的那些。
这样的合适增艳材料的其它实例包括但不限于抗坏血酸葡糖苷、维生素C、视黄醇和视黄醇衍生物、水溶性甘草提取物、熊果提取物、皱叶酸模提取物、乳蛋白(包括水解乳蛋白)、N,N,S-三(羧甲基)半胱胺、齐墩果酸、紫苏油、胎盘提取物、草莓虎耳草、葡萄提取物、Azadirachta indica A. Juss. Var.、光果甘草、海巴戟、Naringi crenulata (Roxb)Nicolson、川芎、Asmunda japonica Thumb.、Stellaria medica (L.) cyr.、垂盆草、女贞子、Ilex purpurea Hassk、Emblica、芹菜素、ascorbyl palmitol、carruba polyphenol、橙皮素、氢醌、inabata polyphenol、异甘草素、山柰酚-7-新橙皮糖、L-含羞草碱、木犀草素、油溶性甘草提取物、oxa acid、异硫氰酸苯酯、水飞蓟素、T4CA、四氢姜黄素、unitrienol、熊果-油酸、UVA/URSI、N,N,S-三(羧甲基)半胱胺、cococin、TDPA、羧半胱胺、cococin、紫苏子提取物、紫苏提取物、刺柏酸、stenolama chusana (L.) ching或其任何组合。
本公开的化妆剂可包含皮肤缓和或皮肤愈合活性物质。适用于本文的皮肤缓和或皮肤愈合活性物质包括泛酸衍生物(包括泛醇、右泛醇、乙基泛醇)、芦荟、尿囊素、红没药醇和甘草酸二钾。可将安全且有效量的皮肤缓和或皮肤愈合活性物质加到本公开的化妆剂,优选以形成的化妆剂重量计约0.1%至约30%,更优选约0.5%至约20%,还更优选约0.5%至约10%。本公开的局部化妆剂还可包含安全且有效量量的红没药醇。红没药醇为天然产生的不饱和单环萜烯醇。
它是洋甘菊提取物/油的主要活性成分。红没药醇可源于合成(d,1-α-异构体或(+/-)-α-异构体)或天然((-)-α-异构体),可作为基本纯化合物或化合物的混合物使用(例如,来自诸如洋甘菊的天然源的提取物)。红没药醇(α-红没药醇)的α形式在各种化妆品中用作皮肤调理剂或缓和剂。本文所用,“红没药醇”包括洋甘菊提取物或油及其任何异构体和互变异构体。合适的红没药醇化合物可以商品名α-红没药醇作为来自Dragoco(Totowa,N.J.)的天然材料商购获得,也可以商品名α-红没药醇作为来自Fluka(Milwaukee, Wis.)的合成材料商购获得。在本公开的化妆剂中,化妆剂优选包含以化妆剂重量计约0.001%至约50%、更优选约0.01%至约20%、甚至更优选约0.01%至约15%、还更优选约0.1%至约10%且甚至更优选约0.1%至约5%的红没药醇。
本公开的化妆剂可包含天然产生的分子。这样的活性物质能够用作消炎剂、皮肤增艳剂、皮肤增亮剂、皮肤光滑/愈合剂、清洁剂等。它们可源于天然或合成。天然来源的材料也可进一步衍生化(例如,在从天然源提取后制备的酯或醚衍生物)。所有形式,包括盐,均被认为在本公开的范围内。例如,可在化妆剂中包含包括或得自辣木提取物、橄榄油或橄榄提取物、葡萄藤(包括白藜芦醇单、二和/或三乙醇酸酯)、植物和水果提取物的分子。使用时,化妆剂优选包含以化妆剂重量计约0.00001%至约10%、更优选约0.2%至约5%、还优选约0.5%至约2%。
本公开的化妆剂可包含抗微生物或抗真菌活性物质。这样的活性物质能够破坏微生物,防止微生物的生长或防止微生物的致病作用。可将安全且有效量的抗微生物或抗真菌活性物质加到本公开的化妆剂,优选约0.0001%至约10%,更优选约0.01%至约5%,且还更优选约0.05%至约2%。
抗微生物和抗真菌活性物质的实例包括β-内酰胺类药物、喹诺酮类药物、环丙沙星、诺氟沙星、四环素、红霉素、阿米卡星、2,4,4-三氯-2-羟基二苯醚、3,4,4-三氯均二苯脲、苯氧基乙醇、苯氧基丙醇、苯氧基异丙醇、多西环素、卷曲霉素、氯己定、金霉素、土霉素、克林霉素、乙胺丁醇、羟乙磺酸己脒定、甲硝唑、喷他脒、庆大霉素、卡那霉素、lineomycin、美他环素、乌洛托品、米诺环素、新霉素、奈替米星、巴龙霉素、链霉素、妥布霉素、咪康唑、盐酸四环素、红霉素、锌红霉素、依托酸红霉素、硬脂酸红霉素、硫酸阿米卡星、盐酸多西环素、硫酸卷曲霉素、葡糖酸氯己定、盐酸氯己定、盐酸金霉素、盐酸土霉素、盐酸克林霉素、盐酸乙胺丁醇、盐酸甲硝唑、盐酸喷他脒、硫酸庆大霉素、硫酸卡那霉素、lineomycinhydrochloride、盐酸美他环素、马尿酸乌洛托品、扁桃酸乌洛托品、盐酸米诺环素、硫酸新霉素、硫酸奈替米星、硫酸巴龙霉素、硫酸链霉素、硫酸妥布霉素、盐酸咪康唑、酮康唑、盐酸金刚烷胺、硫酸金刚烷胺、羟甲辛吡酮、对氯代间二甲苯酚、制霉菌素、托萘酯、吡啶硫酮锌和克霉唑。
可用于本文的活性物质的优选实例包括选自水杨酸、过氧化苯甲酰、3-羟基苯甲酸、乙醇酸、乳酸、4-羟基苯甲酸、乙酰水杨酸、2-羟基丁酸、2-羟基戊酸、2-羟基己酸、顺式视黄酸、反式视黄酸、视黄醇、植酸、N-乙酰基-L-半胱氨酸、硫辛酸、壬二酸、花生四烯酸、过氧化苯甲酰、四环素、布洛芬、萘普生、氢化可的松、对乙酰氨基酚、间苯二酚、苯氧基乙醇、苯氧基丙醇、苯氧基异丙醇、2,4,4'-三氯-2-羟基二苯醚、3,4,4'-三氯均二苯脲、羟甲辛吡酮、盐酸利多卡因、克霉唑、咪康唑、酮康唑、硫酸新霉素及其混合物的那些活性物质。
暴露于紫外光可能导致角质层过度剥落和质感变化。因此,本公开的化妆剂可任选包含防晒活性物质。本文所用“防晒活性物质”包括防晒剂和物理阻光剂。合适的防晒活性物质可以是有机或无机的。
可用于本发明的无机防晒剂包括以下金属氧化物:平均初级粒度约15nm至约100nm的二氧化钛、平均初级粒度约15nm至约150nm的氧化锌、平均初级粒度约15nm至约150nm的氧化锆、平均初级粒度约15nm至约500nm的氧化铁及其混合物。在用于本发明时,无机防晒剂以化妆剂重量约0.1%至约20%的量存在,优选约0.5%至约10%,更优选约1%至约5%。
多种常规的有机防晒活性物质适用于本文。Sagarin等人在Cosmetics Scienceand Technology(化妆品科学与技术)(1972)的第VIII章,第189页及以后公开了许多合适的活性物质。具体的合适防晒活性物质包括,例如:对氨基苯甲酸、其盐及其衍生物(乙酯、异丁酯、甘油酯;对-二甲氨基苯甲酸);邻氨基苯甲酸盐(酯)(邻氨基苯甲酸盐;甲酯、薄荷酯、苯酯、苄酯、苯基乙酯、芳樟酯、萜品酯和环己烯酯);水杨酸酯(戊酯、苯酯、辛酯、苄酯、薄荷酯、甘油酯和二丙二醇酯);肉桂酸衍生物(薄荷酯和苄酯,α-苯基肉桂腈;肉桂酰基丙酮酸丁酯);二羟基肉桂酸衍生物(伞形酮、甲基伞形酮、甲基乙酰基伞形酮(methylaceto-umbelliferone));三羟基肉桂酸衍生物(七叶亭、甲基七叶亭、瑞香素和葡糖苷、七叶苷和瑞香苷);烃(二苯基丁二烯、茋);二亚苄基丙酮和亚苄基乙酰苯;萘酚磺酸盐(2-萘酚-3,6-二磺酸和2-萘酚-6,8-二磺酸的钠盐);二羟基萘甲酸及其盐;邻-和对-羟基联苯二磺酸盐;香豆素衍生物(7-羟基、7-甲基、3-苯基);二唑(2-乙酰基-3-溴吲唑、苯基苯并噁唑、甲基萘并噁唑、各种芳基苯并噻唑);奎宁盐(硫酸氢盐、硫酸盐、氯盐、油酸盐和鞣酸盐);喹啉衍生物(8-羟基喹啉盐、2-苯基喹啉);羟基-或甲氧基-取代的二苯甲酮;尿酸和紫尿酸;鞣酸及其衍生物(例如六乙基醚);(丁基卡必基)(6-丙基胡椒基)醚;氢醌;二苯甲酮类(羟甲氧苯酮(oxybenzene)、磺异苯酮(sulisobenzone)、二羟苯酮(dioxybenzone)、苯酰间苯二酚(benzoresorcinol)、2,2,4,4-四羟基二苯甲酮、2,2-二羟基-4,4'-二甲氧基二苯甲酮、辛苯酮(octabenzone));4-异丙基二苯甲酰基甲烷;丁基甲氧基二苯甲酰基甲烷;氰双苯丙烯酸乙酯;氰双苯丙烯酸辛酯;[3-(4'-甲基亚苄基boman-2-酮)、对苯二亚甲基二樟脑磺酸和4-异丙基-二苯甲酰甲烷。在这些当中,对甲氧基肉桂酸2-乙基己酯(可作为PARSOL MCX购得)、4,4-叔丁基甲氧基二苯甲酰基-甲烷(可作为PARSOL 1789购得)、2-羟基-4-甲氧基二苯甲酮、辛基二甲基-对氨基苯甲酸、棓酰棓酸三油酸酯、2,2-二羟基-4-甲氧基二苯甲酮、4-(双(羟基-丙基))氨基苯甲酸乙酯、2-氰基-3,3-二苯基丙烯酸2-乙基己酯、水杨酸2-乙基己酯、对氨基苯甲酸甘油酯、水杨酸3,3,5-三甲基环己酯、邻氨基苯甲酸甲酯、对二甲基氨基苯甲酸或氨基苯甲酸酯、对-二甲基-氨基-苯甲酸2-乙基己酯、2-苯基苯并咪唑-5-磺酸、2-(对-二甲基氨基苯基)-5-磺苯并噁唑酸、氰双苯丙烯酸辛酯和这些化合物的混合物是优选的。
可用于本公开的化妆剂中的更优选有机防晒活性物质为对甲氧基肉桂酸2-乙基己酯、丁基甲氧基二苯甲酰基甲烷、2-羟基-4-甲氧基二苯甲酮、2-苯基苯并咪唑-5-磺酸、对二甲基氨基-苯甲酸辛酯、氰双苯丙烯酸辛酯及其混合物。
同样,在化妆剂中特别有用的是例如在1990年6月26日授予Sabatelli的美国专利号4,937,370和1991年3月12日授予Sabatelli & Spirnak的美国专利号4,999,186中公开的那些防晒活性物质。其中公开的防晒剂在单个分子中具有两个不同的生色团部分,它们表现出不同的紫外辐射吸收光谱。生色团部分之一主要在UVB辐射范围吸收,另一个在UVA辐射范围强烈吸收。
这类防晒剂的优选成员为2,4-二羟基二苯甲酮的4-N,N-(2-乙基己基)甲基-氨基苯甲酸酯;与4-羟基二苯甲酰基甲烷的N,N-二-(2-乙基己基)-4-氨基苯甲酸酯;与4-羟基二苯甲酰基甲烷的4-N,N-(2-乙基己基)甲基-氨基苯甲酸酯;2-羟基-4-(2-羟基乙氧基)二苯甲酮的4-N,N-(2-乙基己基)甲基-氨基苯甲酸酯;4-(2-羟基乙氧基)二苯甲酰基甲烷的4-N,N-(2-乙基己基)-甲基氨基苯甲酸酯;2-羟基-4-(2-羟基乙氧基)二苯甲酮的N,N-二-(2-乙基己基)-4-氨基苯甲酸酯;和4-(2-羟基乙氧基)二苯甲酰基甲烷的N,N-二-(2-乙基己基)-4-氨基苯甲酸酯及其混合物。
尤其优选的防晒活性物质包括4,4'-叔丁基甲氧基二苯甲酰基甲烷、对甲氧基肉桂酸2-乙基己酯、苯基苯并咪唑磺酸和氰双苯丙烯酸辛酯。
使用安全且有效量的有机防晒活性物质,通常为化妆剂重量的约1%至约20%,更通常约2%至约10%。确切量将取决于选择的一种或多种防晒剂和所需的防晒因子(SPF)。
本公开的化妆剂可包含选自湿润剂、保湿剂或皮肤调理剂的调理剂。可使用多种这些材料,并且每种材料可以化妆剂的重量计约0.01%至约20%、更优选约0.1%至约10%且还更优选约0.5%至约7%的水平存在。这些材料包括但不限于胍、尿素、乙醇酸和乙醇酸盐(例如铵和季烷基铵)、水杨酸、乳酸和乳酸盐(例如铵和季烷基铵)、任何形式的芦荟(如芦荟胶);多元醇,如山梨糖醇、甘露糖醇、木糖醇、赤藓糖醇、甘油、己三醇、丁三醇、丙二醇、丁二醇、己二醇等;聚乙二醇;糖(如蜜二糖)和淀粉;糖和淀粉衍生物(例如烷氧基化葡萄糖、果糖、氨基葡萄糖);透明质酸;乳酰单乙醇胺;乙酰单乙醇胺;泛醇;尿囊素;及其混合物。在1990年12月11日授予Orr等人的美国专利号4,976,953中所述的丙氧基化甘油也可用于发明。
也可使用糖和相关材料的各种C1-C30单酯和多酯。这些酯衍生自糖或多元醇部分和一个或多个羧酸部分。这样的酯材料进一步描述于1977年1月25日授予Jandacek的美国专利号2,831,854、美国专利号4,005,196;1977年1月25日授予Jandacek的美国专利号4,005,195、1994年4月26日授予Letton等人的美国专利号5,306,516;1994年4月26日授予Letton等人的美国专利号5,306,515;1994年4月26日授予Letton等人的美国专利号5,305,514;1989年1月10日授予Jandacek等人的美国专利号4,797,300;1976年6月15日授予Rizzi等人的美国专利号3,963,699;1985年5月21日授予Volpenhein的美国专利号4,518,772;和1985年5月21日授予Volpenhein的美国专利号4,517,360。
优选调理剂选自尿素、胍、蔗糖多酯、泛醇、右泛醇、尿囊素及其组合。
另外,局部化妆剂可包含常规的化妆辅料和添加剂,例如防腐剂、抗氧化剂、脂肪物质、油、水、有机溶剂、有机硅、增稠剂、润肤剂、乳化剂、防晒剂、消泡剂、表面活性剂、填充剂、多价螯合剂、阴离子、阳离子、非离子或两性聚合物或其混合物、推进剂、酸化剂或碱剂、染料、着色料/着色剂、磨料、皮肤感觉剂、收敛剂、颜料或纳米颜料或通常在化妆品组合物中配制的任何其它成分。适用于本公开的组合物并且常规用于皮肤护理行业的这样的化妆品成分描述于例如The CTFA Cosmetic Ingredient Handbook(CTFA化妆品成分手册),Second Edition (1992),但不限于此。
本公开的化妆剂可以而不限于以洗剂、乳状洗剂、乳膏和油、乳液中的油、水性物质、凝胶、水凝胶、洗发剂、毛发冲洗剂、毛发调理剂、发膏、染发剂、毛发上色剂、毛发染色的预处理剂或后处理剂以及分毛所用的涂剂等形式存在。
本公开化妆剂的制剂类型可以为任何类型,包括溶液体系、可溶体系、乳液体系、凝胶体系、粉末分散体系或水油两相体系。
虽然已说明和描述了本公开的具体实施方案,但对本领域的技术人员显而易见,可在不脱离本公开的范围下进行各种其它变化和修改。因此,旨在附加权利要求中覆盖所有这样的变化和修改,并且所有这样的变化和/或修改均被认为在本文描述的本公开的范围内。
Claims (20)
1.一种化妆垫,所述化妆垫包括:
由非织造材料构成的顶层;
以允许通过底层通风的方式构成的底层;和
在顶层和底层之间的至少一个加热元件。
2.权利要求1所述的化妆垫施涂器,其中所述至少一个加热元件为放热加热源。
3.权利要求2所述的化妆垫施涂器,其中所述放热加热源通过使放热加热源暴露于空气来启动。
4.权利要求3所述的化妆垫,所述化妆垫还包括在顶层和底层之间的空气扩散层。
5.权利要求4所述的化妆垫,所述化妆垫还包括制剂层,其中所述制剂层包括至少一个制剂顶层、至少一个制剂底层和在制剂顶层和制剂底层之间的一种或多种产品。
6.权利要求5所述的化妆垫,其中所述一种或多种产品为乳剂、凝胶剂、洗剂、乳膏剂、浆液或混悬剂。
7.权利要求1所述的化妆垫,其中所述化妆垫在密封的包装内。
8.权利要求1所述的化妆垫,其中所述底层包括一个或多个用于通风的口。
9.权利要求1所述的化妆垫,其中所述底层包括用于通风的透气材料。
10.权利要求1所述的化妆垫,其中所述至少一个加热元件为单阶段加热元件。
11.权利要求1所述的化妆垫,其中所述至少一个加热元件为双阶段加热元件。
12.权利要求1所述的化妆垫,所述化妆垫还包括在顶层和底层之间的指袋。
13.一种施加一种或多种化妆品的方法,所述方法包括:
将化妆垫施加到皮肤的一个或多个皮肤区域;所述化妆垫包括:
由非织造材料构成的顶层;
允许通过底层通风的底层;和
在顶层和底层之间的至少一个加热元件。
14.权利要求13所述的方法,其中施加一种或多种化妆品的步骤包括将一个或多个手指插入化妆垫的指袋,其中所述指袋位于顶层和底层之间。
15.权利要求13所述的方法,其中施加一种或多种化妆品的步骤包括将化妆垫附接到装置或施涂器。
16.权利要求6所述的化妆垫,其中所述一种或多种产品包含化妆剂或皮肤病学试剂。
17.权利要求16所述的化妆垫,其中所述化妆剂为肽、小分子、蛋白质、植物或水果提取物、维生素、油、有机油、蛋白质或其混合物。
18.一种使用化妆垫的方法,所述方法包括打开化妆垫,将至少一个手指滑入化妆垫,并释放在化妆垫中容纳的制剂,其中所述制剂包含一种或多种化妆剂或皮肤病学试剂,并且化妆垫施加到皮肤、身体或毛发的区域中。
19.一种系统,所述系统包括具有至少一个加热元件的化妆垫,其中所述化妆垫附接到装置或施涂器,并且在化妆垫内容纳至少一种包含化妆剂的制剂,并且所述系统用于将化妆剂施加到受试者的皮肤、手、足、毛发或脸。
20.权利要求19所述的系统,其中所述系统为手治疗或足治疗系统。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062958194P | 2020-01-07 | 2020-01-07 | |
US62/958194 | 2020-01-07 | ||
PCT/US2021/012227 WO2021141926A1 (en) | 2020-01-07 | 2021-01-06 | Method, and system for multi-layer cosmetic pads and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115135199A true CN115135199A (zh) | 2022-09-30 |
Family
ID=76655724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180008337.5A Pending CN115135199A (zh) | 2020-01-07 | 2021-01-06 | 多层化妆垫的方法和系统及其用途 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210205125A1 (zh) |
EP (1) | EP4087441A4 (zh) |
JP (1) | JP2023509478A (zh) |
KR (1) | KR20220125285A (zh) |
CN (1) | CN115135199A (zh) |
AU (1) | AU2021206185A1 (zh) |
BR (1) | BR112022013398A2 (zh) |
CA (1) | CA3166903A1 (zh) |
TW (1) | TWI771865B (zh) |
WO (1) | WO2021141926A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107530119B (zh) | 2015-02-19 | 2021-05-07 | 凯蒂森特生物医药公司 | 用于产生热量的医疗装置和使用它的治疗方法 |
CA3160895A1 (en) | 2019-12-10 | 2021-06-17 | Niquette Hunt | Medical devices for generating heat and methods of treatment using the same |
KR102685199B1 (ko) * | 2023-04-07 | 2024-07-12 | 김회철 | 파우치 일체형 패드 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1491271A (zh) * | 2001-10-25 | 2004-04-21 | ������������ʽ���� | 发热组合物、使用其的发热体和制备发热体的方法 |
US20060217790A1 (en) * | 2005-03-28 | 2006-09-28 | Ohshin Mlp Co., Ltd. | Sheet-like face pack and kits for face packs |
US20080292936A1 (en) * | 2007-05-23 | 2008-11-27 | American Power Conversion Corporation | Manifold for fuel cells |
CN104093382A (zh) * | 2012-01-31 | 2014-10-08 | 桐灰化学株式会社 | 发热器具 |
KR20180001824U (ko) * | 2016-12-09 | 2018-06-19 | 김주원 | 고마쥬 클렌징 에센스가 함침된 화장용 패드 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4323155B2 (ja) * | 2002-10-31 | 2009-09-02 | マイコール株式会社 | 発熱体 |
US6902335B2 (en) * | 2003-05-08 | 2005-06-07 | R.P. Scherer Technologies, Inc. | Hand held dispensing and application apparatus |
US7211070B2 (en) * | 2003-12-01 | 2007-05-01 | Abraham Ebbie Soroudi | Device and method for exothermic treatment of eyelid diseases |
US20050196562A1 (en) * | 2004-03-04 | 2005-09-08 | Keizo Ota | Self-heating and adhesive device |
WO2008072189A1 (en) * | 2006-12-11 | 2008-06-19 | The Procter & Gamble Company | Single-use personal care products and kits comprising same |
CN201617955U (zh) * | 2010-03-17 | 2010-11-03 | 李淑红 | 一种单面医用检查治疗垫 |
US20130345649A1 (en) * | 2012-06-26 | 2013-12-26 | Sealed Air Corporation(Us) | Self-Heating Patch |
EP2912922B1 (en) * | 2012-10-29 | 2019-03-27 | Forever Young International, Inc. | Temperature changing blankets |
JP5671180B1 (ja) * | 2014-07-30 | 2015-02-18 | ユニ・チャーム株式会社 | 使い捨ての化粧パッド |
CA3083428A1 (en) * | 2017-11-26 | 2019-05-31 | Casemed Engineering, Llc | Hand-held applicator |
KR102051327B1 (ko) * | 2018-05-30 | 2019-12-03 | 김재형 | 음이온 및 원적외선을 방사하는 발열팩 |
-
2021
- 2021-01-06 CA CA3166903A patent/CA3166903A1/en active Pending
- 2021-01-06 EP EP21738448.6A patent/EP4087441A4/en not_active Withdrawn
- 2021-01-06 AU AU2021206185A patent/AU2021206185A1/en not_active Abandoned
- 2021-01-06 WO PCT/US2021/012227 patent/WO2021141926A1/en unknown
- 2021-01-06 CN CN202180008337.5A patent/CN115135199A/zh active Pending
- 2021-01-06 JP JP2022541620A patent/JP2023509478A/ja active Pending
- 2021-01-06 US US17/142,252 patent/US20210205125A1/en active Pending
- 2021-01-06 KR KR1020227026686A patent/KR20220125285A/ko not_active Application Discontinuation
- 2021-01-06 BR BR112022013398A patent/BR112022013398A2/pt unknown
- 2021-01-07 TW TW110100626A patent/TWI771865B/zh active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1491271A (zh) * | 2001-10-25 | 2004-04-21 | ������������ʽ���� | 发热组合物、使用其的发热体和制备发热体的方法 |
US20060217790A1 (en) * | 2005-03-28 | 2006-09-28 | Ohshin Mlp Co., Ltd. | Sheet-like face pack and kits for face packs |
US20080292936A1 (en) * | 2007-05-23 | 2008-11-27 | American Power Conversion Corporation | Manifold for fuel cells |
CN104093382A (zh) * | 2012-01-31 | 2014-10-08 | 桐灰化学株式会社 | 发热器具 |
KR20180001824U (ko) * | 2016-12-09 | 2018-06-19 | 김주원 | 고마쥬 클렌징 에센스가 함침된 화장용 패드 |
Also Published As
Publication number | Publication date |
---|---|
CA3166903A1 (en) | 2021-07-15 |
US20210205125A1 (en) | 2021-07-08 |
EP4087441A4 (en) | 2023-06-07 |
EP4087441A1 (en) | 2022-11-16 |
KR20220125285A (ko) | 2022-09-14 |
JP2023509478A (ja) | 2023-03-08 |
AU2021206185A1 (en) | 2022-08-11 |
BR112022013398A2 (pt) | 2022-09-13 |
TW202135756A (zh) | 2021-10-01 |
WO2021141926A1 (en) | 2021-07-15 |
TWI771865B (zh) | 2022-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI771865B (zh) | 多層化妝墊,以及其系統及用途 | |
CN103442702B (zh) | 黑色素改良组合物及其使用方法 | |
RU2732398C2 (ru) | Композиция для местного нанесения, содержащая экстракты pichia anomala и корня цикория | |
TWI679992B (zh) | 局部美白組合物及其使用方法 | |
EP3332762B1 (en) | Topical composition containing glycerin and yeast extract | |
CN102300551A (zh) | 使用皮肤和/或毛发护理活性物质调节哺乳动物的角质组织 | |
CA2945731A1 (en) | Topical gel cream composition | |
JP2005503335A (ja) | 糖アミンを含有するスキンケア組成物 | |
AU2005221169A1 (en) | Treatment of keratinous tissue | |
CN101175469A (zh) | 使用包含氯化十六烷基吡啶鎓的个人护理组合物来调节哺乳动物的角质组织 | |
EP2059221A1 (en) | Skin care composition | |
JP2002542177A (ja) | 哺乳類のケラチン性組織の状態を調節する方法 | |
JP2006515329A (ja) | ヘキサミジン組成物を用いた哺乳類のケラチン組織の調整 | |
WO2002015873A2 (en) | Personal care compositions containing adhesive elastomeric polymer and inorganic colloid | |
JP2012041302A (ja) | 皮膚化粧料 | |
CN102727406B (zh) | 含白花百合提取物的组合物及其用途 | |
US20090143714A1 (en) | Regulation of Mammalian Keratinous Tissue Using Skin and/or Hair Care Actives | |
KR20160123753A (ko) | 피부미백용 조성물 | |
CN102525851B (zh) | 含有欧洲百合提取物的组合物及其用途 | |
EP1952796A1 (en) | Skin care compositions | |
CA2559877A1 (en) | Treatment of keratinous tissue | |
KR20190023651A (ko) | 피부미백용 조성물 | |
RU2778810C2 (ru) | Композиция для местного нанесения, содержащая глицерин и дрожжевой экстракт | |
Davi de Lacerda et al. | COS DERM | |
WO2011084824A1 (en) | Compositions and methods for increasing cellular fat and bleaching skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40081779 Country of ref document: HK |
|
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220930 |